Etiology of Bacterial Meningitis in Ethioia, 2007 - 2011 :  A Retrospective Study by Ahmed, Arslan
  
 
 
ETIOLOGY OF BACTERIAL MENINGITIS IN 
ETHIOPIA, 2007 – 2011: A RETROSPECTIVE STUDY  
Thesis submitted as a part of the Master of Philosophy Degree in International Community Health. 
 
 
ARSLAN AHMED 
 
Supervisor: PROF. DOMINIQUE A. CAUGANT, Ph.D 
Co-supervisors: DR. ABRAHAM ASEFFA, M.D, Ph.D 
DR. GUNNSTEIN NORHEIM, Ph.D 
 
SEPTEMBER, 2012 
 
University of Oslo 
Faculty of Medicine 
Institute of General Practice and Community Medicine 
Section for International Health 
  
ii 
 
Table of contents 
Acknowledgements ........................................................................................................................ vi 
List of abbreviations: .................................................................................................................... vii 
Abstract: .......................................................................................................................................... 1 
Chapter One: INTRODUCTION ................................................................................................. 3 
1.1. Bacterial meningitis: ........................................................................................................ 3 
1.2. Other causes of meningitis: .............................................................................................. 3 
1.3. Disease definition: ............................................................................................................ 4 
1.4. Epidemiology of bacterial meningitis: ............................................................................. 5 
1.4.1. Streptococcus pneumoniae: ...................................................................................... 5 
1.4.2. Neisseria meningitidis:.............................................................................................. 6 
1.4.3. Haemophilus influenzae type b: ................................................................................ 7 
1.4.4. Neonatal meningitis: ................................................................................................. 7 
1.4.5. Other organisms of bacterial meningitis: .................................................................. 8 
1.5. Pathophysiology of bacterial meningitis: ......................................................................... 8 
1.5.1. Bacterial invasion: .................................................................................................... 8 
1.5.2. Inflammatory response: ............................................................................................ 9 
1.5.3. Neuronal damage: ................................................................................................... 10 
1.6. Clinical presentation:...................................................................................................... 10 
1.7. Complications of bacterial meningitis: .......................................................................... 11 
1.8. Diagnosing bacterial meningitis: .................................................................................... 11 
1.9. Treatment: ...................................................................................................................... 13 
1.10. Prevention: .................................................................................................................. 13 
  
iii 
 
1.11. Meningitis belt: ........................................................................................................... 15 
Chapter two: MENINGITIS IN ETHIOPIA ............................................................................. 18 
2.1. Ethiopia: country profile ................................................................................................ 18 
2.1.1. Demographics: ............................................................................................................ 18 
2.1.2. Climate: ...................................................................................................................... 19 
2.1.3. Economy: .................................................................................................................... 19 
2.1.4. Health profile: ............................................................................................................. 19 
2.2. Meningitis in Ethiopia: ................................................................................................... 22 
2.3. Gaps in literature: ........................................................................................................... 23 
2.4. Rationale of study: ......................................................................................................... 24 
Chapter three: METHODOLOGY AND STUDY DESIGN .................................................... 27 
3.1. Brief description of the project: ..................................................................................... 27 
3.2. Collaborating institutes: ................................................................................................. 27 
3.3. Objectives of study: ........................................................................................................ 28 
3.3.1. Primary objective: ................................................................................................... 28 
3.3.2. Secondary objectives: ............................................................................................. 28 
3.4. Study design: .................................................................................................................. 28 
3.5. Study sites: ..................................................................................................................... 30 
3.5.1. University of Gondar Medical Hospital, Gondar:................................................... 30 
3.5.2. Awassa Referral Hospital, Awassa: ........................................................................ 30 
3.6. Study Period: .................................................................................................................. 31 
3.7. Inclusion criteria for cases: ............................................................................................ 32 
3.8. Exclusion criteria: .......................................................................................................... 32 
  
iv 
 
3.9. Study population: ........................................................................................................... 32 
3.10. Target population:....................................................................................................... 33 
3.11. Sample size: ................................................................................................................ 33 
3.12. Data sources: ............................................................................................................... 33 
3.13. Data collection: ........................................................................................................... 33 
3.14. Data handling:............................................................................................................. 35 
3.14.1. Data entry: ............................................................................................................... 35 
3.14.2. Statistical analysis: .................................................................................................. 35 
3.15. Ethical considerations: ................................................................................................ 35 
3.16. Participant confidentiality: ......................................................................................... 37 
3.17. Expected benefits of the study: ................................................................................... 37 
3.18. Funding: ...................................................................................................................... 38 
3.19. Project timeline: .......................................................................................................... 38 
Chapter four: RESULTS ............................................................................................................ 40 
4.1. Gondar University Hospital: .......................................................................................... 40 
4.1.1. Age-wise and sex-wise distribution of bacterial meningitis: ...................................... 40 
4.1.2. Seasonal effect on the incidence of bacterial meningitis: ........................................... 42 
4.1.3. Organisms of bacterial meningitis: ............................................................................. 43 
4.1.4. Seasonal variations among the various agents of bacterial meningitis: ..................... 49 
4.2. Awassa Referral Hospital: .............................................................................................. 52 
4.2.1. Age wise and sex wise distribution of bacterial meningitis:................................... 52 
4.2.2. Effect of seasonal variation of the incidence of bacterial meningitis: .................... 53 
4.2.3. Clinical feature of bacterial meningitis: .................................................................. 54 
  
v 
 
4.2.4. Outcome of bacterial meningitis: ............................................................................ 56 
4.2.5. Adverse outcomes of bacterial meningitis: Death .................................................. 57 
4.2.6. Adverse outcomes of bacterial meningitis: Sequelae ............................................. 58 
Chapter five: DISCUSSION AND RECOMMENDATIONS: ................................................. 59 
5.1. Discussion: ..................................................................................................................... 59 
5.2. Limitations of the study: ................................................................................................ 64 
5.3. Future recommendations: ............................................................................................... 66 
Chapter six: REFERENCES ...................................................................................................... 68 
Appendix I: Retrospective data collection form: ............................................................................. i 
Appendix II: Characterization of etiological agent from Ethiopian CSF samples from 2002-2003 
by RT-PCR: .................................................................................................................................... ii 
 
  
  
vi 
 
Acknowledgements 
This study has been an exciting experience for me. As I conclude with the write-up, I realize that 
this work could not have been possible without the help of my supervisor, co-supervisors and the 
collaborating staff. As an early stage researcher working on my first research project I was 
always in need of guidance. In this regard I am grateful to my supervisor, Prof. Dominique A. 
Caugant for being patient with my mistakes and encouraging me and helping me out at each step.  
I would extend my deepest gratitude to my co-supervisors Dr. Abraham Aseffa and Gunnstein 
Norheim for providing me valuable feedbacks in the light of their experience. I must thank 
Gunnstein Norheim for his continuous support during the process of study and also 
accompanying me on my initial visit to Ethiopia. I owe my deepest gratitude to the staff at 
Norwegian Institute of Public Health particularly Jan Oksnes for the training I received on 
laboratory detection techniques and Real-Time PCR. 
My sincere appreciation goes to the collaborating staff at Armauer Hansen Research Institute, 
Gondar University Hospital and Awassa Referral Hospital in Ethiopia. The help of Mr. Yarid 
Merid at Awassa and Mr. Kasim Molla at Gondar made the data collection easier. I am highly 
grateful to Mrs. Wude Mihret, Tsehaynesh Lema and Melaku Yedenekachew who were always 
very helpful during my visits to Ethiopia. I would thank the wonderful people of Ethiopia 
because it was for their love that I never felt away from home. 
In the end, I would like to thank all my friends who encouraged me and supported me through 
the long hours of thesis writing. Finally, it was the continuous support of my parents, my brother, 
my sister and my grandmother that served as the main motivational and driving force. I could not 
have done it without your support. 
And for all the people of Ethiopia who could not make it in their struggle against meningitis. 
May your souls always rest in peace!     
 Arslan Ahmed 
30
th
 August’ 2012. 
  
vii 
 
List of abbreviations: 
AHWO African Health Workforce Observatory 
AHRI Armauer Hansen Research Institute 
BBB Blood Brain Barrier 
CNS Central nervous system 
CFR Case fatality rate 
CSF Cerebrospinal fluid 
EFNS European Federation of Neurological Societies 
GDP Gross domestic product 
GAVI Global Alliance for Vaccine and Immunization 
Hib Haemophilus influenzae type b 
HSDP Health Sector Development Program  
LPS Lipopolysaccharide 
  
viii 
 
LP Lumbar puncture 
MVP Meningitis Vaccine Project 
MLST Multilocus sequence typing 
NRERC National Health Research Ethics Review Committee 
NIPH Norwegian Institute of Public Health  
OMV Outer membrane vesicle  
PCR polymerase chain reaction  
REK Regional committee for medical and healthcare research ethics 
SNNPR Southern Nations, Nationalities and Peoples’ Region  
TBM Tuberculous meningitis 
WHO World health organization 
 
  
  
 
 
Abstract: 
Bacterial meningitis is a serious infection and is associated with considerable mortality and 
morbidity in various parts of the world. It has a global epidemiology but sub-Saharan Africa 
bears the highest burden of the disease. Located in the eastern horn of Africa, Ethiopia is also 
endemic for bacterial meningitis with frequent meningococcal epidemics occurring every few 
years particularly in the dry season from December to June. Although it is generally considered a 
disease of the childhood, no age group is exempt from the infection. In the developing countries 
the fatality rate associated with bacterial meningitis can often be very high. In the absence of 
proper treatment, bacterial meningitis is known to cause serious neurological complications 
which may persist throughout the life.   
Bacterial meningitis has remained a serious health concern for Ethiopia for the past few decades. 
Formulation of effective preventive strategies can only be based on the estimates of the recent 
epidemiological trends of bacterial meningitis. The study conducted focuses primarily on the 
recent trends of the disease in two major cities of Ethiopia i.e. Gondar and Awassa. The data 
collected retrospectively from the hospitals’ clinical and laboratory records provide an insight 
into the epidemiology, demographical characteristics such as age-wise and sex-wise distribution 
of the disease, seasonal variation of the etiological agents and the treatment outcomes of 
bacterial meningitis in Ethiopia. The bacterial cultures of the cerebrospinal fluid (CSF) and the 
Gram staining results from the past five years were studied to find out the estimated prevalence 
of the common agents of bacterial meningitis. The clinical records from the hospital wards 
provided insight into the various common clinical signs and symptoms associated with bacterial 
meningitis and the treatment outcomes including the various common complications of the 
disease. 
The study showed a higher prevalence of bacterial meningitis in males with an observed male to 
female ratio of 1.7:1 at Gondar and 1.9:1 at Awassa. The disease incidence was highest in small 
children and young adults. Infants were the most commonly affected age group at Gondar 
University Hospital which formed almost 27% of the cases. Young adults between 15-24 years 
of age were among the most effected age groups at Awassa Referral Hospital and also accounted 
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to about 27% of the cases. A marked effect of seasonal variation was observed with more cases 
occurring in the summer months. Almost 35% of the cases of bacterial meningitis at Gondar 
were recorded in the months of May and June. Culture specific results show that this variation 
was most pronounced in meningococcal disease in which almost 2/3 of the cases (67%) occurred 
in the dry season during the second quarter of the year i.e. April to June.  Among the various 
agents of bacterial meningitidis, Streptococcus pneumoniae was the most common organism 
which was identified in the CSF cultures of 35 patients (35.3%). This was followed by Neisseria 
meningitidis from 27 cases (27.3%) and Haemophilus influenzae from 9 cases (9.1%).  
In the absence of laboratory facilities the diagnosis of bacterial meningitis largely depends upon 
the clinical signs and symptoms at the time of presentation. The most common clinical 
symptoms that were recorded from the clinical records of Awassa Referral Hospital include high 
grade fever (88.9% of the cases), neck rigidity (74.8%), headache (69.6%) and nausea and 
vomiting (59.3%). Altered mental state was present in more than half of the patients. Various 
treatment outcomes were recorded including complete recovery (56.7%), partial recovery with 
sequelae (9.2%) and death which was recorded in 23.5% of the cases.  
The study had been conducted with the aim to provide data that will be useful for formulation 
and implementation of preventive strategies against bacterial meningitis in Ethiopia. The results 
represent two major and demographically distinct cities of Ethiopia. These results can be 
generalized to give estimate of the recent trends and the current prevalence of bacterial 
meningitis in Ethiopia which may provide basis for future research not only in these study sites 
but also in other cities of Ethiopia.    
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Chapter One: INTRODUCTION 
 
Meningitis is the inflammation of membranes covering the brain and spinal cord. Meningitis can 
be due to both infectious and non-infectious causes. Infectious causes are more common and on 
the basis of the causative organism, they can be classified as pyogenic or bacterial meningitis, 
viral meningitis, tuberculous and aseptic meningitis. Bacterial meningitis is a serious condition 
which demands early diagnosis and prompt treatment.  
1.1. Bacterial meningitis: 
Bacterial meningitis is the most prevalent type of meningitis. The most common agents of 
bacterial meningitis are Haemophilus influenzae type b, Neisseria meningitidis, serogroups A, B, 
C, W135 and Y, and Streptococcus pneumoniae. Globally, bacterial meningitis affects 
approximately 1.2 million people each year and causes almost 170,000 deaths 
(1)
. In the absence 
of proper treatment, the mortality rate associated with bacterial meningitis can be as high as 50% 
(2)
. For this reason bacterial meningitis is among the 10 leading causes of mortality due to 
infections worldwide 
(3)
. Survivors of bacterial meningitis can suffer from serious neurological 
complications such as deafness, blindness, cognitive and intellectual impairment etc which often 
persist throughout the life. Although no age group is exempt from acquiring the infection, 
bacterial or pyogenic meningitis has the highest incidence in the first year after birth. 
Adolescence also shows a higher incidence between 15-24 years of age which accounts for 
almost 30% of all the cases of bacterial meningitis 
(4)
.  
1.2. Other causes of meningitis: 
Apart from bacterial meningitis many other causes of meningitis exist; these are viral meningitis, 
tuberculous meningitis (TBM) and other non-infectious causes of aseptic meningitis. Viral 
meningitis, which is usually less severe than bacterial meningitis, is a result of meningeal 
infection by various viruses. A virus may only be identified in 50% of the cases; the most 
common of those identified are some enteroviruses 
(5)
. Common childhood infections such as 
chicken pox and measles have often been implicated in viral meningitis. TBM is caused by 
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Mycobacterium tuberculosis and is a very severe form of disseminated tuberculosis. Like acute 
bacterial meningitis, TBM also results in high rates of neurological complications and often 
lifelong sequelae. Without proper treatment the mortality rate with TBM can be very high 
(6)
. 
Tuberculosis is a disease linked to low socio-economic status; therefore TBM is rare in 
developed countries. The individuals most at risk of acquiring TBM are the young children 
already exposed to primary tuberculosis, immunocompromised such as very old age, 
malnourished or patients with concurrent HIV infection 
(7)
. Aseptic meningitis is a term reserved 
for the meningitis for which initial clinical examination and routine laboratory tests (including 
Gram staining and CSF culture) fail to reveal a definite cause. The etiology of aseptic meningitis 
often includes viral, fungal or TBM. Non-infectious causes of aseptic meningitis such as 
malignancies with brain metastasis or some medications notably sulphamethoxazole and non-
steroidal anti-inflammatory drugs have also been identified 
(8)
.   
1.3. Disease definition: 
By definition “bacterial meningitis is an inflammatory response to bacterial infection of the 
membranes covering the brain and spinal cord” (9). In literature various practical definitions 
have been used to set up an inclusion criterion for cases of bacterial meningitis. A study 
conducted in Mali in 2009 on the persistence and spread of meningococcal meningitis defined a 
“suspected case” as the one which is only clinically diagnosed. A “probable case” was defined as 
a suspected case with a cloudy CSF sample. A “case” was confirmed only after the etiology was 
established biologically 
(10)
. Some studies defined cases based on clinical signs and symptoms 
specific to bacterial meningitis such as neck stiffness, altered consciousness, high grade fever, 
seizures etc 
(11)
. But clinical symptoms are often non-specific and vary from patient to patient. 
Other studies in literature have defined a “case” based on WHO recommendations which defines 
a case as a patient with purulent CSF and with a cell count of >100 cells/mm3 
(12)
. But this 
definition requires readily available laboratory assistance which may not be possible in many 
hospitals in the developing countries of the world. Due to this reason a more clinical definition of 
meningitis is used in many studies to formulate an inclusion or exclusion criteria. 
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1.4. Epidemiology of bacterial meningitis: 
The exact incidence of bacterial meningitis worldwide remains difficult to estimate due to the 
variation in the surveillance mechanisms present in the different parts of the world. While 
surveillance is well established in the industrialized world, the incidence of bacterial meningitis 
is underreported in many developing countries. In the past decade a sharp decline in the 
incidence of bacterial meningitis in the developed countries has been witnessed, where the 
incidence now lies between 1-3 per 100,000 population 
(13)
. This decrease is attributed to the 
introduction of vaccines against common pathogens of bacterial meningitis. Development of 
vaccine against H. influenzae type b and its routine use in childhood immunization schedules has 
nearly eradicated the corresponding organism from developed countries. Similarly, a substantial 
reduction in childhood pneumococcal meningitis has been observed following the introduction of 
the conjugate vaccine covering seven different serotypes of S. pneumoniae 
(14)
. But still in some 
developing countries the incidence may be as high as 800 cases per 100,000 population 
(15)
.  
Although most of the environmentally acquired bacteria have the potential to cause meningitis, 
the majority of the bacterial meningitis cases are due to S. pneumoniae, N. meningitidis and H. 
influenzae type b (Hib). In recent years, due to the decline in the cases of H. influenzae, S. 
pneumoniae and N. meningitidis have become the most common causes of bacterial meningitis 
(16)
. The etiology of bacterial meningitis varies with the population under study, the geographical 
conditions and the season of the year. This is easily demonstrated by the sharp increase in the 
incidence of meningococcal meningitis during the dry season in some parts of the sub-Saharan 
Africa. This is particularly attributed to the dry climate and harsh winds, thus causing the “ill 
wind bringing meningitis” effect (17). Different age groups show high susceptibility to certain 
organisms. Gram negative enteric rods such as Escherichia coli, Klebsiella pneumoniae, Proteus 
mirabilis and some other organisms such as Listeria monocytogenes are more common during 
the neonatal period, while S. pneumoniae and N. meningitidis are more common in the children 
and young adults 
(18)
.  
1.4.1. Streptococcus pneumoniae: 
S. pneumoniae is one of the most common causes of bacterial meningitis worldwide. It is a 
capsulated bacterium which has 93 serotypes based on the different polysaccharide 
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characteristics of the capsule. Most of the serotypes are capable of causing disease but majority 
of the infections in the developing countries are caused predominantly by serotypes 1 and 5 
(19)
.  
Although no age group is exempt from pneumococcal meningitis, it usually affects small 
children under the age of 2 years. The other age group with high susceptibility to pneumococcal 
infection is the old age. Immunocompromised people are also at a higher risk of acquiring 
pneumococcal meningitis 
(20)
. Like N. meningitidis and H. influenzae, S. pneumoniae spreads as 
respiratory droplets. The high rates of pneumococcal infections may partly be due to the high 
carriage rates among the general population. Children under 6 years of age have the highest rates 
of nasopharyngeal carriage 
(20)
. Due to this reason pneumococcal disease has become the leading 
cause of vaccine preventable deaths in that age group 
(21)
. The incidence in children under 5 
years of age is estimated to be 17 cases per 100,000 population, which is also associated with a 
high mortality rate often reaching up to 73% in some parts of the developing world 
(22)
. 
Pneumococcal meningitis incidence may exhibit mild seasonal variations. Although some strains 
of S. pneumoniae have been implicated in large outbreaks, causing widespread epidemics is not 
considered typical of pneumococcal disease
 (23)
 
(24)
.  
1.4.2.  Neisseria meningitidis: 
N. meningitidis is an obligate commensal residing in the human nasopharynx. The highest 
incidence of nasopharyngeal carriage of N. meningitidis is in adolescents especially those 
residing in overcrowded spaces. Particularly prone are school-going children and college 
students, household contacts of meningococcal patients and also military recruits 
(25)
. Other 
factors that may predispose to meningococcal carriage include lower socio-economic status and 
concurrent viral or bacterial respiratory tract infection. In such individuals the carriage rates can 
be as high as 34% 
(26)
 
(27)
. Recent estimates show that the global incidence of meningococcal 
disease is 500,000 per annum with a worldwide mortality rate of 10% 
(28)
. N. meningitidis can 
exist with or without a polysaccharide capsule. However, nearly all of the meningococcal 
meningitis infections are caused by the capsulated form. Based on the polysaccharide 
characteristics N. meningitidis can be divided into at least 12 different serogroups. Serogroups A, 
B, C, W135, X and Y are isolated in almost 90% of the infections 
(15)
. The serogroup distribution 
is often related to the age of the patient and more importantly to the geographical location 
(26)
. 
Serogroup A is frequently isolated from CSF samples of meningitis patients in sub-Saharan 
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Africa where it causes epidemics. In these epidemics the incidence is very high, often reaching 
up to 1 case per 100 population. The fatality rates even with treatment can be more than 10%
 (29)
 
(30)
. Serogroups B and C are more common as a cause of meningitis in Europe, America and 
Australia
 (31)
. Serogroup C has occasionally been the cause of epidemics and outbreaks in these 
countries 
(32)
. The incidence of serogroup C has been reduced considerably in the recent years 
due to the development of effective conjugate vaccines 
(29)
. Other serogroups such as serogroups 
W135, X and Y are prevalent in some parts of Africa and US respectively 
(2)
. Meningococcal 
disease may develop into a widespread blood infection known as meningococcemia, which is a 
serious and often fatal form of meningococcal infection. 
1.4.3. Haemophilus influenzae type b: 
H. influenzae is a common respiratory pathogen which can occur either as capsulated or un-
capsulated form. The difference in structure of the polysaccharide capsule is the basis for the 
division of H. influenzae into 6 serotypes; a, b, c, d, e and f 
(33)
. Out of these 6 serotypes, 
serotype b is associated with most of the meningitis infections. Once known as the most common 
cause of acute bacterial meningitis, the incidence of Hib has been reduced substantially, 
principally due to the introduction of vaccine. A conjugate protein polysaccharide vaccine that 
was introduced in early 1990s has been very effective in controlling Hib infections 
(16)
. The 
infection occurs usually in children less than 5 years of age and is rare in adults. The incidence 
varies in different parts of the world but it is generally estimated to be higher in Africa where the 
incidence is around 46 per 100,000 population. In Europe this incidence is much lower and is 
around 16 cases per 100,000 population 
(34)
. In unimmunized patients, the mortality rate is 
estimated to be almost 43% 
(34)
.  
1.4.4. Neonatal meningitis: 
Neonates are particularly prone to acquiring bacterial meningitis possibly due to the immaturity 
of their immune system. Even in the industrialized countries the incidence of neonatal meningitis 
is about 0.3 cases per 1000 live births 
(35)
. In some parts of Africa and South Asia the incidence 
in much higher and is estimated to be around 6.1 per 1000 live birth 
(36)
. Although the mortality 
rates are less than 10% 
(37)
, the high incidence of long term neurological complications is the 
matter of most concern 
(38)
. The organisms causing neonatal meningitis include group B 
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streptococci which accounts to about half of all the cases of neonatal bacterial meningitis. This is 
followed by Gram negative enteric rods particularly E. coli which is isolated in 20% of the cases. 
Another 5-10% of the cases are caused by L. monocytogenes 
(39)
 
(40)
. In developing countries the 
incidence of gram negative rods such as E. coli and K. pneumoniae may be much higher 
(37)
. A 
recent decrease in the incidence of group B streptococci is attributed to the antibiotic prophylaxis 
given pre-partum to the neonates at risk 
(41)
.  
1.4.5. Other organisms of bacterial meningitis: 
Other uncommon causes of bacterial meningitis include Staphylococcus aureus, Pseudomonas 
aeruginosa and some other enterococci. They are usually associated with nosocomial infections 
and may be acquired after trauma or some surgical interventions. However, with advancement of 
antibiotic therapy, immunization and aseptic techniques during interventions, their incidence is 
on a rapid decline 
(42)
.  
1.5. Pathophysiology of bacterial meningitis: 
The majority of the symptoms produced as a result of bacterial meningitis are as a result of the 
inflammatory response to the invading organism 
(43)
. This inflammatory response is a step wise 
process of acute and chronic humoral immunity directed against the pathogens that produces the 
effects of meningitis. The events involved in the development of the disease can be summarized 
as follows: 
1.5.1. Bacterial invasion: 
High grade bacteremia or the invasion of the blood by bacteria having the potential to cause 
meningitis is the foremost step in the development of bacterial meningitis. Alternatively, 
meningitis can occur as a consequence of direct invasion of the central nervous system (CNS) 
which may result from dural defects or local infection of the CNS. Contagious spread of 
infection from sinuses and internal ear is also a recognized cause of meningitis in a small portion 
of patients 
(44)
. But usually the infection of the meninges follows a high grade bacteremia 
(45)
. 
The exact site at which the transmission of the bacteria from blood to the CNS occurs is 
uncertain. The choroid plexus is believed to be associated with this transmission. This was 
demonstrated by Daum et al. in 1978, who observed the transmission of H. influenzae via the 
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choroid plexus 
(46)
. Recently, with the advancement in imaging and laboratory techniques, certain 
other sites that may also serve as a potential point of entry to the CNS have been identified. 
Studies have documented the presence of meningococci in the meninges in addition to the 
choroid plexus 
(47)
. Similarly, pneumococcal infiltration of the leptomeningeal vessels has also 
been documented 
(48)
.   
The blood brain barrier (BBB) and the sophisticated tight junctions restrict the bacterial entry to 
the CNS. The breach of the BBB or the blood-CSF barrier is therefore crucial to the entry of the 
bacteria into the CNS. This is achieved by the presence of certain proteins on the surface of the 
bacteria which cause a breach in the BBB. The identified proteins include Streptococcal proteins 
such as CbpA, meningococcal PilC1 adhesin and outer membrane proteins that assist in bacterial 
adhesion and subsequent endocytosis 
(49)
. Similar adhesive molecules are also identified in GBS 
(50)
 and E. coli, both of which are a common cause of meningitis in newborns. The opacity 
proteins expressed on the outer membrane of N. meningitidis (Opa and Opc) serve the purpose of 
bacterial adhesion and endocytosis 
(51)
.  
1.5.2. Inflammatory response: 
With the bacterial invasion occurs the inflammatory response of the endothelial cells. This 
inflammatory response leads to the leukocyte infiltration which is a multi step process involving 
the accumulation of leukocytes particularly the granulocytes. The presence of granulocytes in the 
CSF is therefore important in the diagnosis of bacterial meningitis. The process of bacterial 
invasion and inflammation seem to occur parallel, with the later assisting the former by 
increasing the permeability of the BBB. The products of leukocyte activations which include the 
matrix metalloproteinases, nitric oxide and others affect the BBB and the blood-CSF barrier by 
causing it to break 
(52)
.  This provides bacteria the opportunity to infiltrate the barrier and gain 
entry into the CNS. Once inside the sub-arachnoid space, the bacteria replicate. The increase in 
number of bacteria along with their autolysis enhances the process of inflammation which is the 
basis of pathogenesis of bacterial meningitis.         
The inflammatory response to the bacteria is a complex process involving a variety of 
inflammatory cells notably endothelial cells, mast cells and perivascular macrophages 
(53)
. 
Bacterial components capable of inducing host inflammatory response include peptidoglycans, 
lipoprotein, lipopolysaccharides and lipoteichoic acid. Experiments showed that their potential to 
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trigger the inflammatory mediators remains unaltered even if heat killed bacteria are inoculated 
into the host 
(54)
 
(55)
.   
1.5.3. Neuronal damage: 
Bacterial meningitis has a very high incidence of neurological complications with almost 50% of 
the patients showing neurological deficits to varying degree 
(56)
. The neuropathy results from the 
inflammation of the subarachnoidal space, vasculitis and edema of the brain tissue. Neuronal 
injuries to the cerebral cortex, hippocampus and inner ear are also an important cause for most of 
the complications 
(57)
. The damaged caused to the CNS by the invading bacteria is attributed to 
multiple factors such as bacterial toxins, the inflammatory response to the invading organism or 
the cytotoxic elements of the complement system. In addition to these factors, the indirect effect 
of these intracranial complications on the surrounding structures of the CNS is responsible for 
the symptoms due to the “space occupying lesion” effect that accompanies meningitis. The 
bacterial toxins for S. pneumoniae include pneumolysin, which is a pore forming cytolysin and 
hydrogen peroxide 
(58)
. The pneumolysin preferentially affects the mitochondrial membrane 
causing the damage by virtue of its pore forming activity 
(59)
. The key virulence factors for N. 
meningitidis and other related gram negative bacteria are the lipopolysaccharides and 
lipooligosaccharides. These endotoxins trigger the release of interleukin-6 and tumor necrosis 
factor alpha (TNF ) along with other cytokines mediators. These mediators are responsible for 
the tissue or organ damage and subsequently the symptoms that are characteristic of bacterial 
meningitis 
(60)
.    
1.6. Clinical presentation: 
Clinical assessment of severity of bacterial meningitis is crucial for identifying the factors that 
affect the outcome of bacterial meningitis. Most common signs and symptoms include the 
“classic triad” of fever, headache and neck stiffness. However, these classical symptoms occur in 
less than half of the cases 
(61)
. Usually, the symptoms are non-specific early in the course of the 
disease with fever, headache and malaise as the main presenting features. Specific symptoms 
such as neck stiffness, photophobia and impairment of consciousness represent meningeal 
irritation and develop later as the disease progresses 
(62)
. Signs of meningeal irritation contribute 
significantly to the diagnosis of bacterial meningitis, more so in the settings devoid of modern 
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day laboratory facilities. But these signs may not be present in unconscious patients, very small 
children or in the immunocompromised patients 
(63)
. Such cases may present as a diagnostic 
challenge. Other symptoms that may accompany bacterial meningitis include nausea, vomiting, 
back rigidity, shock, seizures, unconsciousness and bleeding from skin 
(64)
. Petechial rash is a 
characteristic of infection by N. meningitidis and represent meningococcemia.  
In the developing countries with minimal laboratory facilities these clinical symptoms form the 
mainstream for the diagnosis of bacterial meningitis. Owing to the importance of these clinical 
symptoms many studied were conducted to find out the incidence of the various common signs 
and symptoms of bacterial meningitis. A study in Gondar University Hospital, Ethiopia on 151 
children showed that vomiting was present in almost 80% of the cases. This was followed by 
fever (75%), stiff neck (70%) and altered mental state (49%) 
(65)
.  
1.7. Complications of bacterial meningitis: 
If left untreated, bacterial meningitis can cause various complications such as hearing defects, 
speech abnormalities, intellectual impairment, learning difficulties and seizures
 (66) (67)
 
(68)
. The 
rate of these complications can be as high as 50% 
(69)
. The chances of acquiring these 
complications increase depending upon the organism involved, age of the patient, the severity of 
disease and the quality of treatment provided 
(70)
. These complications are more common in 
small children and can cause serious neurological defects that often tend to be long lasting. 
Included among these complications are focal neurological deficits such as paralysis of the 
limbs, developmental disabilities, seizures, cerebral abscesses and hydrocephalus 
(71) (72)
. Most of 
these complications in children usually resolve within 2-3 years but 10% of the children may 
develop complications that persist throughout the life 
(73)
.  
1.8. Diagnosing bacterial meningitis: 
Bacterial meningitis is best diagnosed by clinical assessment assisted by laboratory evidence of 
the causative organism. The presence of bacteria in the CSF forms the basis of the diagnosis of 
bacterial meningitis. Bacterial detection rate in CSF can be as high as 90%, as compared to a 
mere 50% detection rate when blood samples are used for the same purpose 
(45)
. A lumbar 
puncture (LP) is done to draw CSF samples from the patients. LP is a minimally invasive 
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procedure but not without possible complications. It is therefore, subjected to the decision of the 
attending physician, especially in the very young, very old, immunocompromised or patients 
with skin infections.  
Various laboratory tests are used for the diagnosis of bacterial meningitis but CSF cultures and 
polymerase chain reaction (PCR) are considered as “gold standard” (74). Other laboratory 
techniques include Gram staining, the oxidase test and latex agglutination test. On Gram staining 
N. meningitidis appear as Gram-negative diplococci, which resemble “coffee bean”. S. 
pneumoniae are Gram-positive diplococci with lanceolate appearance often occurring in short 
chains. H. influenzae are small Gram-negative pleomorphic rods which depict random 
arrangements 
(75)
. Gram staining of CSF and CSF culture are reliable methods for detecting 
bacterial meningitis, but in case of prior antibiotic treatment the yield can be low. Studies 
conducted by the American Academy of Pediatrics on 231 patients during 2001-2004 showed a 
decrease in CSF culture from 88% to 70% if the patients were pre-treated with antibiotics 
(76)
. 
The biochemistry and cytology of CSF aspirate is very helpful in the overall diagnosis of 
bacterial meningitis, initiation of antibiotic therapy and accessing the progress of treatment. The 
CSF characteristics highly suggestive of bacterial meningitis include an elevated CSF cell count 
(>500 cells/l), predominantly neutrophils. Increased protein levels in the CSF (>1g/l) is also an 
important diagnostic factor and indicates disruption of the blood-brain or the blood-CSF barrier. 
Similarly increased levels of CSF lactate (>0.3g/l) and lowered CSF/blood ratio of glucose 
(<0.4) is also suggestive of bacterial meningitis 
(77)
. Although these CSF values are not highly 
specific and can also be associated with some other conditions, when combined with other 
clinical and laboratory investigations they serve as a valuable tool for the diagnosis of bacterial 
meningitis. 
For characterization of various strains of bacterial meningitis into serogroups and serotypes, 
immunological methods are used. For genetic differentiation, techniques such as PCR and 
multilocus sequence typing (MLST) are used. A study was conducted by Norwegian Institute of 
Public Health (NIPH) in Southern Nations, Nationalities and Peoples’ Region (SNNPR) and 
North Gondar zone of Ethiopia in 2002-2003 for characterization of various strains of 
meningococci. The study relied on similar techniques including MLST for identification of the 
current meningococcal strains in Ethiopia 
(78)
. A study on laboratory based surveillance of 
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bacterial meningitis was carried out in Khartoum, Sudan in 2004-2005. CSF samples from 1,830 
suspected cases of bacterial meningitis were taken. CSF samples were inoculated on Trans-
Isolate medium 
(79)
 and PCR was carried out on those samples. The study concluded that by 
using laboratory surveillance at least 30% more cases can be diagnosed which otherwise would 
remain undiagnosed 
(11)
. In both the studies mentioned above Trans-Isolate medium was used for 
the transport and storage of CSF samples as it can support the survival of N. meningitidis, S. 
pneumoniae and H. influenzae for at least 3 months 
(79)
. 
1.9. Treatment: 
Acute bacterial meningitis is a serious emergency requiring timely and proper treatment. Before 
the 20
th
 century, acute bacterial meningitis was almost always fatal 
(80)
. The invention of 
antibiotics has drastically improved the outcome of bacterial meningitis. Initiation of proper 
treatment within 6 hours of presentations reduces the mortality rates by more than 8 times 
(81)
. 
Delay in initiation of antibiotic therapy is shown to be the single most important risk factor 
related to the outcome of bacterial meningitis 
(82)
. The European Federation of Neurological 
Societies (EFNS) taskforce on bacterial meningitis highly recommends initiation of antibiotic 
treatment within the first hour of admission 
(83)
. The usual treatment is with a broad spectrum 
third generation cephalosporin which is usually given empirically while the laboratory results are 
awaited 
(84)
.   
1.10. Prevention: 
Bacterial meningitis is a vaccine preventable disease and vaccines form a cornerstone in its 
prevention. Various types of vaccines are currently being used to prevent bacterial meningitis. 
Hib protein polysaccharide conjugate vaccine which was introduced in early 1990s is widely 
used in many countries throughout the world as a part of national childhood immunization 
schemes 
(16)
. It is due to this vaccine that the incidence of Hib has fallen sharply in the past few 
years to the extent of virtual disappearance in some industrialized countries of the world
 (85)
. 
Similarly, pneumococcal conjugate vaccine has been used for pneumococcal meningitis 
prevention with encouraging results. First introduced in 2000 in the United States as a 7-valent 
conjugate vaccine 
(86)
, the efficacy of the vaccine was about 80% for the targeted serotypes 
(87)
. 
The incidence of pneumococcal disease has also fallen sharply, particularly in the countries 
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where the vaccine is incorporated into the national immunization schemes. A striking example is 
the White Apache Mountains area in Eastern Arizona where the incidence of pneumococcal 
disease due to the seven serotypes was reduced from 275 per 100,000 to almost none within the 
course of one decade from 1997-2006 
(88)
. Pneumococcal conjugate vaccine is now being 
introduced with support from The Global Alliance for Vaccine and Immunisation (GAVI) in 
developing countries. With the effectiveness of the Hib and the pneumococcal vaccines in view, 
WHO now recommends the inclusion of Hib 
(89)
 and pneumococcal conjugate vaccine 
(90)
 into 
the immunization schedule of all countries.  
Currently two types of vaccines are being used against various serotypes of N. meningitidis: pure 
polysaccharide vaccines and conjugate vaccines 
(91) (26)
. The conjugate vaccines are considered 
superior to the polysaccharide vaccines as the later is known to be less immunogenic in children 
and provides only a temporary protection ranging from three to five years 
(18)
 
(91)
. Both pure 
polysaccharide and conjugate vaccines against serogroups A, C, Y and W135 have been 
developed. Conjugate vaccine against the serogroup C is now regularly used in routine childhood 
immunization schedules in some European countries 
(30)
. An example is United Kingdom where 
after the introduction of vaccine in 1999, the incidence of meningitis due to serogroup C has fell 
more than 94% in immunized people. Some reduction was also noted in un-immunized people 
supporting the belief that the vaccine also provides herd immunity 
(92)
. The vaccine has also 
resulted in a significant decline in the nasopharyngeal carriage rates of serogroup C. 
Development of a vaccine against serogroup B has encountered difficulties due to the poor 
immunogenic nature of the polysaccharide capsule. This has led to the development of vaccines 
targeting other structures such as an outer membrane vesicle (OMV) vaccine. Success has been 
reported with the use of OMV vaccine in New Zealand with an overall efficacy ranging between 
70-80% 
(93)
. With the success of OMV vaccine against serogroup B, prospects of developing a 
similar outer membrane vesicle vaccine against other sergroups such as serogroup A and W135 
are also underway. The development of such vaccines may pave the way for preventing most of 
the meningitis cases in sub-Saharan Africa 
(94)
.  
Meningococcal serogroup A is more common in sub-Saharan parts of Africa where it is often the 
cause of widespread epidemics. A conjugate vaccine which is currently believed to be the most 
effective vaccine against Neisseria meningitidis serogroup A is available in some countries of the 
sub-Saharan Africa under the Meningitis Vaccine Project (MVP). The MVP, which is an 
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initiative by the WHO and Program for Appropriate Technology in Health (PATH) aims to 
provide low cost serogroup A conjugate vaccine to a target population of 250 million across 25 
African countries 
(95)
. The vaccine has currently been introduced in Burkina Faso, Mali, Niger, 
parts of Nigeria and Chad, but not yet in Ethiopia
 (96)
. The successful implementation of 
meningococcal serogroup A conjugate vaccine in Ethiopia requires a detailed information about 
the prevalence trends of meningococcal meningitis and its current circulating strains in Ethiopia. 
For the purpose of vaccine design and implementation a study was conducted in 2002-2003 to 
investigate the prevalence and circulating strains of meningococcal meningitis is Ethiopia. The 
study was conducted in Southern Nations, Nationalities and Peoples’ Region (SNNPR) and 
North Gondar Zone in Ethiopia. The study found antigenic variation between the meningococcal 
A strains of 2002-2003 when compared with that of previous strains and recommended further 
investigation of these potential antigens for implementation of preventive measures and 
introduction of new vaccines 
(97)
. 
1.11. Meningitis belt: 
The highest burden of bacterial meningitis occurs in an area of sub-Saharan Africa known as the 
“meningitis belt”, described by Léon Lapeyssonnie in 1963 (98). The area of meningitis belt that 
stretched from Mali to Sudan in 1963 gradually extended in the past decades. The meningitis belt 
that we know today stretches from Senegal in the west to Ethiopia in the east and includes 400 
million people and 21 nations 
(99)
. This area is characterized by high prevalence of bacterial 
meningitis. Marked seasonal fluctuations occur in the prevalence of meningococcal meningitis 
which rises during the dry season from December to June with incidence as high as 1000 cases 
per 100,000 population during an epidemic 
(100)
. The incidence then falls steeply on the arrival of 
the rainy season. The mechanism by which the dry season affects the incidence of 
meningococcal disease may be multifactoral. Although dry climate and harsh winds may have an 
effect of propagation of meningococcal disease by droplet spread, the more widely accepted 
view is the effect of the dry climate on the integrity of the mucosal surface of nasopharynx. The 
breaks in the mucosal barrier lead to the progression of the carrier state to the invasive infection 
(101) (102)
. The nasopharyngeal carriage rates of N. meningitidis in the area of meningitis belt are 
estimated to be as high as 30% 
(103)
. This high carriage rate further increases the chances of 
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developing or spreading infection during the dry season of the year. Recent studies suggest, 
however, that the carriage rate might be much lower in absence of outbreak 
(104)
.  
 
 
Figure 1: Map of Meningitis Belt 
 
The part of sub-Saharan Africa that constitutes the meningitis belt is characterized by recurrent 
meningococcal outbreaks. The records show that major outbreaks tend to occur every 8–12 years 
(97)
. After the first reported outbreak in 1840 almost 400 epidemics of bacterial meningitis have 
been recorded in the meningitis belt. The largest epidemic was reported in 1996 which affected 
250,000 people and resulted in almost 25,000 deaths and 50,000 disabilities 
(105)
. In addition to 
the major epidemics, smaller isolated outbreaks involving only a community also occur 
frequently. Most of the epidemics have been due to N. meningitidis serogroup A but some 
epidemics due to other serogroups such as serogroup C, X and W135 have also been reported 
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(106)
. The introduction of meningococcal conjugate A vaccine under the MVP may, therefore, 
cause a considerable reduction in the incidence of meningococcal disease in the years to come.  
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Chapter two: MENINGITIS IN ETHIOPIA 
 
2.1.  Ethiopia: country profile 
Located in the Horn of Africa, The Federal Democratic 
Republic of Ethiopia lies at the crossroads between Middle 
East and Africa. Ethiopia is bounded by Eritrea to the north 
and Kenya to the south. The eastern part is bounded by 
Somalia and to the west lies Sudan and South Sudan. 
Ethiopia covers a vast land area of 1.1 million square 
kilometers and is the second most populous country in 
Africa with a population of more than 84 million 
(107)
.  
2.1.1. Demographics: 
Ethiopia’s population continues to grow at a rate of 2.5%, and has increased from 33.5 million in 
1983 to 84 million in 2012 
(108)
. The capital city of Ethiopia is Addis Ababa which is also the 
largest city with a population of almost 3 million. Other large cities of Ethiopia include Mekele, 
Adama, Gondar and Awassa. Ethiopia is one of the least urbanized countries of the world with 
only 17% of the population residing in the urban areas. But in the recent decade rapid 
urbanization has occurred with the urban population increasing at a rate of 4.1% 
(108)
.  
Ethiopia is famous for her ethnic diversity. People from at least 80 different ethnic backgrounds 
reside in Ethiopia. Oromo form the largest ethnic group (34.5%) followed by Amhara (26.9%), 
Somali (6.20%) and Tigray (6.07%) 
(107)
. Due to this reason many native language are spoken in 
Ethiopia. These include Oromifa, Tigrinya and Somali. Amharic is the main language spoken 
and understood throughout Ethiopia. English is the most commonly spoken foreign language. 
The literacy rate still remains low with the adult literacy rate estimated to be about 30%. 
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2.1.2. Climate: 
Most of the area of the country is covered by highlands which make the climate much cooler 
than the neighboring African countries. Many major cities of Ethiopia, including Addis Ababa 
and Gondar, are located at an elevation of more than 2000 meters which provides a considerably 
cooler but much uniform temperature throughout the year. The southern part of Ethiopia 
including the South Nations and Nationalities Peoples’ Region (SNNPR) is located at a lesser 
elevation as compared to the northern part. The capital city of SNNPR, Awassa is located at an 
elevation of 1700m (in contrast to 2000m of Addis Ababa and Gondar). Due to this, Awassa has 
a climate much hotter than the central and northern part of Ethiopia. The seasons can be defined 
by rainfall into rainy season between June to September and a dry season ranging from October 
to February.   
2.1.3. Economy: 
The main domestic product of Ethiopia is agriculture which accounts to about 41% of the total 
GDP and makes up to 80% of the total exports. Agriculture is also the major profession in 
Ethiopia with almost 80% of the population associated with agriculture. Although Ethiopia 
showed highest economical growth within the non-oil dependant African economies in 2007-
2008, the per capita GDP still remains one of the lowest in the world. The poverty rates are very 
high with almost 39% of the population living below the poverty line of earning less than US$ 
1.25 per day.  
2.1.4. Health profile: 
The main health related problems in Ethiopia are due to communicable diseases. The preventable 
causes of death due to communicable diseases account to about 74% of the total deaths. The high 
rates of infectious diseases are due to poor sanitation, unavailability of healthcare facilities and 
lack of trained staff especially in the rural parts of Ethiopia. Another important dilemma for the 
healthcare system is the very high incidence for nutritional deficiencies. The main healthcare 
statistics are provided below: 
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Table 1: An overview of health statistics of Ethiopia 
Life expectancy at birth (Males) 53 years 
Life expectancy at birth (Females) 56 years 
Under 5 mortality rate (per 1000 live births) 106 (135 rural, 99 
urban) 
Maternal mortality rate (per 100,000 live births) 350 
Extended program on immunization (EPI) coverage 72.6% 
Immunization coverage under 1 year of age for Hib 89% 
Doctor/Patient ratio (physician per 100,000 population) 2  
Nurses or mid-wives (per 100,000 population) 24 
Population using improved drinking water sources 38% 
Population using improved sanitation 12% 
Percentage of death due to communicable disease 74% 
Note: All sources are from WHO factsheet 
(109)
 
 
Ethiopia has about 149 hospitals, at least 67 of which are privately owned. There are 1343 health 
centers and 1788 heath stations or health clinics. There are a total of 12488 health posts which is 
the smallest unit of the health care system of Ethiopia. But the attendance at the healthcare 
services and the health coverage remains low due to far distances from the healthcare centers 
coupled with lack of proper transportation 
(110)
.  
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Figure 2: Levels of healthcare system in Ethiopia 
(Source: Human Resources for health: country profile Ethiopia. African Health Workforce Observatory (AHWO), June 2010). 
 
In the past there have been no elaborate health policies although a WHO initiated health policy 
was adopted in 1960s. The emphasis of the policies had been on measures to reduce 
communicability of infectious diseases with the help of community involvement. As most of the 
population lives in rural areas, so priority was given to the rural areas. Recently, a government 
initiative known as Health Sector Development Program (HSDP) has been introduced. It is a 20 
years development program which is split into 5 years smaller programs. The program focuses 
on distribution of health services on equal grounds and encourages the participation of 
community as well as private sectors such as non-government organization (NGOs). Other aims 
include capacity building of the healthcare resources and collaboration at the regional and 
international level with other countries 
(110)
. 
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2.2.  Meningitis in Ethiopia: 
Located on the eastern part of meningitis belt, Ethiopia is one of the countries which are most 
affected with bacterial meningitis. The first reported outbreak in Ethiopia dates back to 1901, 
which was followed by outbreaks in 1935, 1940s, 1950s, 1964 and 1977 
(111)
. The largest 
epidemics in Ethiopia were reported in 1981 and 1989, each of which affected almost 50,000 
people 
(112)
. Epidemiological studies on the spread on these epidemics in Ethiopia suggest the 
introduction of meningococcal disease first in western part of Africa. Earliest recorded outbreaks 
of cerebrospinal meningitis occurred in soldiers stationed in Algiers in 1840 and in labourers 
working in present day Ghana in 1900 
(105)
. The epidemic of 1989 that occurred in the eastern 
part of Africa is believed to be spread by pilgrims returning from Mecca 
(101)
. Since the 
introduction of meningococcal disease in Ethiopia, the disease has remained endemic with 
frequent outbreaks. The outbreaks prior to 2001 occurred mostly in the north western, western 
and south western parts of Ethiopia, the areas that are traditionally included in the meningitis 
belt. However, outbreaks in 2001 and afterwards have extended to the eastern parts of the 
country as well 
(113)
. These epidemics were caused mainly by N. meningitidis serogroup A, but 
serogroup C has also been isolated from samples during various outbreaks in 2000 and 2003 
(114)
.  
Apart from N. meningitidis other agents of bacterial meningitis such as Hib and S. pneumoniae 
are also very common. During the year 1993-1995, A study conducted in a pediatric hospital in 
Addis Ababa in 1993-1995 showed that almost 5.5% of all hospital admissions were bacterial 
meningitis. Out of 385 cases diagnosed as bacterial meningitis 74 cases were due to H. 
influenzae, 63 cases were recognized as M. tuberculosis and 46 cases were due to S. pneumoniae. 
Meningococcal meningitis was very rare and was identified only in 6 cases. However, in 196 
cases out of total 385 cases the exact etiology could not be traced
 (115) (116)
. The study also 
reported incidence of antibiotic resistance in S. pneumoniae and H. influenzae. The emerging 
resistance among the organisms causing bacterial meningitis is a matter of serious concern. 
Studies have reported increased resistance to the commonly used antibiotics such as penicillin G 
and chloramphenicol 
(117) (118)
.  
Bacterial meningitis accounts for about 6-8% of all the hospital admissions in Ethiopia and the 
case fatality ratio associated with bacterial meningitis is as high as 22-28%
 (114)
. A study 
conducted at Gondar University Hospital over a span of 5 years from 1998-2003 showed the 
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prevalence of various common agents of bacterial meningitis in children up to the age of 14 
years. N. meningitidis was the most common cause of meningitis and accounted to about 28% of 
the cases. This was followed by S. pneumoniae and H. influenzae which were identified in 7% 
and 6.5% of cases, respectively. S. aureus and Salmonella species were responsible for a small 
number of cases. Another study conducted in Butajira, a town located in south-central Ethiopia, 
reported causes of 10,700 deaths during 1987-2008. The results showed that almost 1% of all 
deaths were due to meningitis 
(119)
. A similar study during the same period reported meningitis as 
a cause of almost 1.9% of all deaths 
(120)
. Both these studies lacked laboratory confirmation and 
relied on “verbal autopsy” to acquire information from the relatives of the deceased. 
Laboratory-based clinical studies on bacterial meningitis are essential for predicting accurately 
the current prevalence of bacterial meningitis and determining the disease causing organisms. 
Only a few studies in Ethiopia are supported by laboratory surveillance. A WHO led study was 
conducted in various African countries including Ethiopia to study the prevalence of various 
agents of bacterial meningitis in infants less than 3 months of age 
 (121)
. Both blood cultures and 
CSF cultures were used to identify the causative organism. The study showed S. pneumoniae 
(24%) and E. coli (24%) to be the most common organism causing bacterial meningitis in 
neonates. Other common agents of bacterial meningitis were Streptococcus pyogenes (22%), 
Salmonella (12%) and H. influenzae (7%).  
2.3.  Gaps in literature: 
A critical review of the literature on bacterial meningitis in Ethiopia highlights the efforts of 
researchers working on meningitis in this region of the world. The work of the pioneers more 
than half a century ago and the subsequent continuation of research with addition of more 
advance laboratory techniques has shaped our knowledge and understanding of meningitis in 
Ethiopia. This has proven beneficial with respect to the control strategies that are being 
implemented now, not only in Ethiopia, but other parts of the world as well. Nevertheless, the 
continuously changing epidemiology, emergence of new strains along with the prospects of 
newer vaccines and advances in laboratory techniques has led to the demand of new research in 
this field. The new research needs to be tailor-made to focus on the changing epidemiology to 
achieve the desired results. With this prospective in mind some of the gaps are identified that 
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need to be filled in order to achieve better understanding and control of bacterial meningitis in 
Ethiopia.  
1) Most of the studies mentioned in the literature were carried out in the epidemic periods, i.e. 
from December to June and less emphasis is laid on non-epidemic periods. This implies that 
most of those studies have focused on meningococcal meningitis and very few studies focused 
on other types of bacterial meningitis, such as H. influenzae and S. pneumoniae. These causes 
bacterial meningitis are also endemic in Ethiopia and are associated with high morbidity and 
mortality and therefore need to be focused on with priority.  
2) A major portion of the studies mentioned have small children as their target group. It is well 
known that bacterial meningitis also has high incidence in elderly and immunocompromised 
people. Therefore, for implementing nationwide policies and preventive measures, data on other 
age groups should also be available.  
3) Laboratory surveillance is essential for proper diagnosis of bacterial meningitis and 
identifying various causative agents. Not all of the studies were assisted with laboratory 
surveillance. The laboratory techniques used in many studies were outdated and did not meet the 
criteria of “gold standard” which is considered vital for clinical research.  
4) Most of the studies were carried out either in a single hospital or a single city. The results 
from one specific area cannot be generalized over the whole population. Generalized results are 
needed to take preventive steps.  
5) The WHO website for Multi Disease Surveillance Centre (MDSC) show no or limited data on 
the etiology of bacterial meningitis in Ethiopia as compared to other countries of meningitis belt 
(122)
. Studies are needed that can provide recent data on bacterial meningitis which is crucial for 
its prevention in Ethiopia.  
2.4. Rationale of study: 
A study is required to investigate the prevalence of different types of bacterial meningitis in 
Ethiopia. The current data is limited and does not cover all common types of bacterial 
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meningitis. Most of the studies mentioned in literature are based on the prevalence of meningitis 
in the epidemic phases. It is also essential to study the epidemiology of bacterial meningitis in 
the non-epidemic phases, i.e. from June to December. Meningococcal meningitis is prevalent 
primarily during the epidemic phases, but pneumococcal meningitis and H. influenzae are 
endemic during the non-epidemic phases as well. Examples from the literature have shown that 
these non-epidemic strains of bacterial meningitis are also responsible for a vast proportion of 
cases of bacterial meningitis throughout the year 
(66)
. Therefore the study is planned to 
investigate the prevalence of these strains in the non-epidemic phases, as their incidence may 
still be considerably higher than the most other countries of the world. 
The incidence of bacterial meningitis varies depending upon the age of the patients, geographical 
location, climate and time of the year. Previous studies have focused primarily on children and 
data on other age groups is required to carry out preventive measures for bacterial meningitis. 
Therefore the study includes all age groups to generate data irrespective of age limitations. Data 
is also needed that can be generalized over the whole population of Ethiopia. To meet this 
requirement the study is planned to be carried out in two different cities geographically and 
climatically different to obtain results that can be generalized. The study has two components, a 
retrospective component that covers the past 5 years and a prospective component that provides 
laboratory surveillance of bacterial meningitis for one year. This laboratory surveillance is 
required to identify the current strains and study their prevalence, with the aim of carrying out 
preventive measures or implementing new vaccines in Ethiopia.  
Several retrospective studies have been conducted in Ethiopia but a study is needed that can 
correlate the clinical symptoms and the severity of disease with the laboratory results to give a 
wider view of the factors affecting the severity of bacterial meningitis. Retrospective data from 
the previous years can help in predicting the current prevalence of various types of bacterial 
meningitis. As Ethiopia is endemic for bacterial meningitis with cases of bacterial meningitis 
presenting in the hospitals throughout the year, therefore, the data available in the hospitals’ 
clinical and laboratory record books can be the most accurate indicator of the current status of 
bacterial meningitis in Ethiopia. These data can also serve as a valuable tool and a reliable 
indicator of the degree of success of the preventive strategies introduced in the past. Similarly, it 
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can also be used to highlight the short comings and provide a basis for identifying corrective 
measures.      
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Chapter three: METHODOLOGY AND STUDY DESIGN 
 
3.1.  Brief description of the project: 
“Surveillance of bacterial meningitis and factors affecting meningococcal disease severity” is a 
project by Norwegian Institute of Public Health (NIPH) in collaboration with Armauer Hansen 
Research Institute (AHRI) in Addis Ababa, Ethiopia. The project aims to study the current 
patterns of bacterial meningitis in Ethiopia with emphasis on meningococcal disease. The project 
has two components: a retrospective study which focuses on the recent trends of bacterial 
meningitis in Ethiopia during the last 5 years and a prospective study to provide continuous 
surveillance of bacterial meningitis for a period of one year. The prospective study is under 
progress with inclusion of new patients and subsequent laboratory analysis on their CSF and 
blood specimens. To achieve better understanding of the overall trends of bacterial meningitis in 
Ethiopia, a period of one year surveillance is the minimal duration required. A delay had 
occurred in the initiation of the prospective study due to the unusually prolonged duration of the 
ethical clearance process that had been unaccounted for. Due to this reason the one year 
surveillance period has not concluded yet. Therefore, the thesis will focus on the retrospective 
component of the study. 
3.2. Collaborating institutes: 
The collaborating institutes include: 
 National Institute of Public Health, Norway (NIPH) 
 Armauer Hansen Research Institute, Addis Ababa, Ethiopia (AHRI) 
 Gondar University Hospital, Gondar 
 Awassa Referral Hospital, Awassa 
 
  
28 
 
Retrospective study 
3.3. Objectives of study: 
3.3.1. Primary objective: 
To study retrospectively the various trends of bacterial meningitis in selected Ethiopian hospitals 
in the previous 5 years from 2007-2011. 
3.3.2. Secondary objectives: 
 To explore the trends of bacterial meningitis in terms of number of cases over time.  
 To find out the prevalence of various etiological factors causing bacterial meningitis. 
 To find out the distribution of bacterial meningitis in terms of age and sex. 
 To study the effect of seasonal variability on the incidence of bacterial meningitis. 
 To describe the most common clinical signs and symptoms associated with bacterial 
meningitis.  
3.4.  Study design: 
The study involves a retrospective collection of clinical and laboratory data from selected 
hospitals in Ethiopia, to provide a quantitative assessment of the recent epidemiological trends of 
bacterial meningitis. The study group constitutes of all consecutive cases of bacterial meningitis 
that presented in Gondar University Hospital and Awassa Hospital during a defined study period. 
During a visit to the study sites before the start of the study the extent of the laboratory and 
clinical data available was assessed with the help of the site co-ordinators of the project. Based 
on this initial assessment, a wide range of data comprising clinical records of patients as well as 
data on laboratory-based detection of bacterial meningitis was found. Therefore, a 
multidimensional approach to study the various clinical, histopathological and biochemical 
aspects of bacterial meningitis was adopted.  
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Due to the better laboratory facilities available at Gondar University Hospital, the data on actual 
causative organisms of bacterial meningitis was used to interpret the prevalence trends of various 
agents of bacterial meningitis. A high input of patients with bacterial meningitis coupled with the 
well-maintained clinical records from the in-patients and emergency departments at Awassa 
Referral Hospital was observed. The data from Awassa were therefore used to calculate the 
prevalence of bacterial meningitis, the frequency of the most common clinical symptoms, rates 
of complications and outcome of the disease. 
The research design is retrospective. Retrospective studies aim at reasoning the outcome of an 
effect back to its antecedent cause. This is in contrast to the prospective studies which aim at 
reasoning from a present antecedent to a future outcome or consequence. Retrospective studies 
have several advantages. They are less time-consuming, more economical and can provide 
valuable results in a very short time period. But they are often subjected to recall bias. This effect 
has been minimized in the current research as the data were recorded directly from the clinical 
and laboratory records. Another drawback with the retrospective studies is that it is often 
difficult to eliminate the effect of confounding variables which affect the outcome of study. 
Possible attempts were made to reduce the effect of confounding variable. Patients who were 
concomitantly affected by other kind of meningitis, such as tuberculous, viral or aseptic 
meningitis and other CNS lesions were not included in the study. However, removing the effects 
of all the confounding variables can be difficult to achieve. Retrospective studies cannot prevent 
the occurrence of an event which has already occurred, but may be helpful in preventing such 
events in the future. Retrospective studies can often be useful in the formation of a hypothesis 
which can then be evaluated in further studies. This forms the basis of the relationship of this 
retrospective study to the overall project.  
The study aimed at providing quantitative assessment of the prevalence of bacterial meningitis in 
Ethiopia and to provide results that may be generalized over the whole Ethiopian population. The 
only study design that permits these characteristics of the research is a quantitative study. 
Quantitative research design can be defined as “the numerical representation and manipulation of 
observations for the purpose of describing and explaining the phenomena that those observations 
reflect” (123). Quantitative research provides details of the direct and indirect variables and allows 
the researcher to measure and quantify the effect. The study is basically a prevalence study and 
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demands the inclusion of all the patients of bacterial meningitis during the defined study period. 
Consequently, no randomization was used and all patients that fulfilled the inclusion criteria 
were included in the study. 
3.5. Study sites: 
The field work was carried out in two tertiary care hospitals from different cities of Ethiopia i.e. 
Gondar University Hospital in Gondar and Awassa Referral Hospital in SNNPR region of 
Ethiopia.  
3.5.1. University of Gondar Medical Hospital, Gondar: 
Gondar is a city in the North-western part of Ethiopia. Administratively, it is located in the 
Amhara region. Previously the capital city of Ethiopia, Gondar is now the third largest city in 
Ethiopia. Famous for its castles, Gondar is a mountainous area with an elevation of 2100 meters 
above the sea level. Due to this reason the climate is much cooler. The average annual 
temperature is 19.2
o
C which ranges from 10
o
C (December and January) to 29
o
C (March to May). 
The total population of Gondar is more than 200,000. Different ethnic groups reside in Gondar, 
out of which Amhara form the majority (88.9%) followed by Tigrayan (6.7%) and Qemant 
(2.4%). Amharic is the main language spoken in the Gondar region.    
The University of Gondar Medical Hospital is the largest hospital in Gondar. It is a 400-bed 
teaching hospital associated with a medical college. The medical college was founded in 1954 
and is the oldest training institute for health professionals in Ethiopia. The hospital covers a wide 
range of area and is a referral hospital for four districts hospitals. It has a range of specialities 
including paediatrics, surgical, gynaecological, psychiatric and an HIV centre. With a staff 
comprising of 400 healthcare personals, including 50 medical doctors, the hospital covers a 
population of four million. The hospital has well established laboratory facilities with a staff of at 
least 25 trained laboratory scientists. 
3.5.2. Awassa Referral Hospital, Awassa: 
Awassa is a city located in the southern part of Ethiopia close to the lake Awassa of the Great 
Rift Valley. The city of Awassa lies 270km to the south of the capital city of Addis Ababa. 
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Awassa belongs to the SNPPR of Ethiopia and is the administrative capital of the region. The 
total population of Awassa is almost 260,000. It lies at an elevation of 1700 meters and the 
temperature ranges between 20
o
C and 30
o
C.   
 
 
Figure 3: Map of Ethiopia showing the study sites and the capital city of Addis Ababa 
Awassa Hospital is the biggest hospital in the city of Awassa and the Southern Nations, 
Nationalities and Peoples' Region (SNNPR). Affiliated with the Awassa University, the hospital 
is a teaching hospital for Awassa Health Science College which was founded in 1996. As a 
tertiary care teaching hospital it is a 350-bed hospital and includes paediatrics, medical, surgical, 
ophthalmology and gynaecological/obstetrical departments. The hospital serves for more than 12 
million people.   
3.6.  Study Period: 
The study includes all consecutive cases of bacterial meningitis that presented in Gondar 
University Hospital and Awassa Referral Hospital during a defined study period. The study 
periods for two study sites differ in length. From Gondar University Hospital retrospective data 
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were collected for the last 5 years from January 2007 till December 2011 (corresponding to the 
Ethiopian calendar from 4
th
 month of 1999 to 5
th
 month of 2004). From Awassa Hospital the data 
was collected for the last 2.5 years from September 2009 till December 2011 (corresponding to 
the Ethiopian calendar from start of 2002 to the 5
th
 month of 2004). The study periods were 
selected to permit the maximum utilization of available data as determined on the preliminary 
visits to the study sites.  
3.7.  Inclusion criteria for cases: 
The patients fulfilling the following criteria were selected for the study: 
 Positive CSF culture or Gram staining results suggestive of bacterial meningitis 
 Clinically diagnosed cases of bacterial meningitis by a medical specialist in the cases 
where a CSF culture or Gram staining were not performed.  
 All age groups that fulfil the above criteria 
3.8.  Exclusion criteria: 
The patients exhibiting the following characteristics were not included in the study: 
 Simultaneous infection with another form of meningitis such as tuberculous, viral or 
fungal meningitis. 
 Presence of another CNS infection that can present with symptoms similar to 
bacterial meningitis such as cerebral malaria or any other CNS lesion. 
3.9.  Study population: 
All the patients with bacterial meningitis that presented in Gondar University Hospital or Awassa 
Referral Hospital during the study period and fulfilling the above mentioned inclusion criteria 
were included in the study and defined as the study population. 
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3.10. Target population: 
The study sites are two different cities with distinct geographical and climatic features. These 
cities are located in the northern and southern part of Ethiopia. Thus the study is carried out with 
the intention of providing results that can be generalized over whole of the Ethiopia. Therefore, 
the target population for this study is the whole Ethiopian population.  
3.11. Sample size: 
No predefined sample size was set. The study included all the cases of bacterial meningitis that 
presented in Gondar University Hospital and Awassa Referral Hospital during the defined study 
period and fulfilled the above mentioned inclusion criteria.     
3.12. Data sources: 
The clinical and laboratory data were collected from the available hospital clinical and laboratory 
records. The patient related clinical data were collected from the hospital clinical records. The 
potential cases were identified by the hospital log books present in the emergency wards, the 
medical, paediatrics and neonatal in-patient wards and also the out-patient registers. The 
laboratory log books for CSF cultures and Gram staining results were also searched to find the 
cases of bacterial meningitis. In addition to the routine log books, separate log books that were 
used during the off-duty hours such as weekends or public holidays were also searched to avoid 
missing any potential study participants. Once the cases were identified from any of these 
sources the original hospital clinical records were accessed with the help of the main record 
room staff. The records were traced using the patient hospital registration number from the log 
books. The original laboratory result slips attached inside these clinical record forms were also 
accessed.   
3.13. Data collection: 
The information obtained from the above mentioned sources were entered into specialized pre-
defined data collection forms (data collection form attached as appendix I). Among the clinical 
details, the signs and symptoms at presentation such as stiff neck, headache, fever, altered mental 
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state, seizures, etc and the treatment outcome were recorded. Demographic details such as age, 
sex and the month of presentation were also recorded. Similarly laboratory findings from the 
laboratory log book such as results of CSF cultures, Gram staining, CSF cell count, proteins and 
glucose level, depending upon their availability, were recorded on the data collection forms. On 
identification of cases, each participant was given a factitious number that was used throughout 
the research to avoid confidentiality issues. The data were recorded by two researchers to avoid 
any bias. Any discrepancy in collection and interpretation of data was relieved with the help of a 
person from the study site who was qualified and familiar with the original data sources (i.e. 
study coordinators).  
 
Table 2: Data variables collected in the retrospective data 
Demographic data Age, sex, city or region and date of 
presentation. 
Clinical history Clinical signs and symptoms at 
presentation such as presence or 
absence of stiff neck, fever, headache, 
altered mental state, seizures and 
petechial rash.  
Presence of any sequelae. 
Treatment outcome Complete recovery, fatal case and 
partial recovery with sequelae. 
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Laboratory results Gram staining of CSF samples, CSF 
culture, CSF cell count, proteins and 
glucose level. 
 
3.14. Data handling: 
3.14.1. Data entry: 
The data from the filled-in data collection forms were then entered into SPSS version 18.0.0 and 
later converted to Excel sheets for convenience during discussions with the study co-ordinators.  
3.14.2. Statistical analysis: 
The results were analyzed using a registered version of SPSS 18.0.0. The statistical analysis was 
conducted to find out the exact proportion of various etiological factors of bacterial meningitis in 
the patients that presented in Gondar University Hospital and Awassa Referral Hospital during 
the defined study period. The various trends of bacterial meningitis over the last 5 years in terms 
of age and sex distribution were studied. The hospital-wise prevalence of bacterial meningitis in 
relation to seasonal variation and the time of the year were also studied. The study also focused 
on the relationship of various clinical signs and symptoms to the overall prognosis and outcome 
of disease.  
3.15. Ethical considerations: 
The approval for the main project “Surveillance of bacterial meningitis and factors affecting 
meningococcal disease severity” was granted by REK “Regionale Komiteer for Medisinsk og 
Helsefaglig Forskningsetikk” (Regional Committee for medical and healthcare research ethics) 
in Norway. Following clearance from REK the protocol was submitted to the National Health 
Research Ethics Review Committee (NRERC) in Ethiopia. Abiding by the regulations of the 
chief collaborating institute in Ethiopia, the Armauer Hansen Research Institute (AHRI) Addis 
Ababa, clearance was also sought from the medical research ethics board of AHRI. Once the 
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ethical clearance was obtained from all of the above mentioned institutes, the institutional review 
boards (IRBs) of the study sites hospitals were requested to grant ethical approval. Once all these 
ethical reviews were sought and the approval granted from all of the above mentioned institutes, 
a final administrative order directing the commencement of the study was issued by the office of 
the medical director of the respective hospitals.  
 
Figure 4: The process of obtaining ethical clearance for the project 
With the commencement of the prospective study and preliminary meeting with the site co-
ordinators at the collaborating hospitals, the need to utilize the retrospective data was 
emphasized. Consequently, the protocol for retrospective study was submitted as an amendment 
to the main prospective study. The approval for the retrospective study amendment was sought 
from all the institutes that had earlier granted the ethical clearance. In addition to the above 
Regional Committee For Medical And 
Healthcare Research Ethics (REK)
(May 2011 - August 2011)
Medical Research Ethics Committee 
at Armauer Research Institute (AHRI)
(May 2011 - June 2011)
National Health Research Ethics 
Review Committee (NRERC)
(June 2011 - October 2011)
Institutional Review Boards (IRBs) of 
study sites
(November 2011 - December 2011)
Final approval letter from the office 
of medical director of the hospital
(December 2011)
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mentioned approvals, an additional approval from the hospital administration was required to 
access the hospital main record room and utilize the retrospective data from the clinical records 
of the patients. As the research is clinical and involves multiple institutions, therefore, the 
process of acquiring ethical clearance was complicated. Taking into account the clinical nature of 
the research and the usual application processing times, the whole process of obtaining the 
ethical clearance took almost 6 months for the main prospective study. The retrospective 
amendment was approved in a course of 3-4 months.  
3.16. Participant confidentiality: 
Safeguarding the patients’ right to confidentiality should be the foremost responsibility of the 
researcher. To ensure this right of confidentiality, all the cases were enrolled with complete 
anonymity. Upon inclusion each participant was provided with an identification number that was 
used throughout the study and during the data analysis and publication of results. The data record 
forms were devised as to not permit the recording of any personal details such as name of the 
patient, the hospital registration number and the address of the patients. The original list of the 
hospital registration numbers that was used to trace the clinical records of the patients was kept 
only with the researcher in a place separate from the collected data. The list will be retained with 
the researcher for a period of 6 months after the publication of the results in order to verify any 
ambiguity that may arise. The list will be discarded after a period of 6 months from the 
publication of results.  
3.17. Expected benefits of the study: 
The study is intended for the host population as being the sole beneficiaries. The retrospective 
data collected from the two study sites will prove helpful in establishing the current prevalence 
of bacterial meningitis in those particular settings. The effect of seasonal variability on various 
types of bacterial meningitis and the age wise and gender wise distribution of disease burden will 
provide useful estimates on the recent trends of bacterial meningitis. The study sites include two 
hospitals located in different cities of Ethiopia which imparts generalization to the results. 
Therefore, the results obtained from the study will also prove helpful for other hospitals in 
Ethiopia working in similar settings. Special emphasis has been laid to ensure the validity of the 
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clinical and laboratory data. This 5-year retrospective study component along with the one year 
prospective study that is in progress may provide valuable data that can be used for further 
research, formulation of preventive strategies and implementation of new vaccines. 
3.18. Funding: 
The project is funded by the Norwegian Research Council (PROJECT NO: 192477) under the 
GLOBVAC fund. The second visit to Ethiopia was funded by Ivar Helles’ Foundation, Norway.  
3.19. Project timeline: 
 
Table 3: Project timeline for the master’s project 
Literature search and protocol writing  May 2011 – June 2011 
First visit to Ethiopia for setting up 
prospective study 
June 2011 – November 2011 
Introductory meetings with collaborating 
institute regarding retrospective study 
June 2011 – July 2011 
Setting up study start-up, recruiting study staff, 
equipment purchase and transfer for the 
prospective study. 
July 2011 – August 2011 
Conducting laboratory optimization and 
training for the recruited staff 
August 2011 – September 
2011 
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Ethical clearance for the retrospective study 
October 2011- December 
2011 
Preparing retrospective study start-up and co-
ordination with the collaborating institutes. 
January 2012 - February 2012 
Second visit to Ethiopia and collection of 
retrospective data 
March 2012 – April 2012 
Data analysis and thesis write up May 2012 – August 2012 
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Chapter four: RESULTS 
 
4.1. Gondar University Hospital: 
The laboratory records from the Gondar University Hospital for the 5 years period from January 
2007 to December 2011 revealed 128 cases of bacterial meningitis that were confirmed either by 
CSF culture or CSF Gram staining or by both. These 128 confirmed cases of bacterial meningitis 
were then analyzed to find out the gender ratios, number of cases in each age group, the most 
common etiological agents of bacterial meningitis and the seasonal variations in the incidence of 
bacterial meningitis due to these etiological agents.  
4.1.1. Age-wise and sex-wise distribution of bacterial meningitis: 
Gender and age were recorded from the laboratory log books in 109 cases. Out of these 109 
laboratory confirmed cases of bacterial meningitis in Gondar University Hospital during the 5 
years study period, 69 (63.3%) were males and 40 (36.7%) were females.  
The male to female ratio was 1.7:1.  
Table 4: M to F ratio in cases of bacterial meningitis in 
Gondar University Hospital during 2007-2011 
Gender Number of cases 
(N) 
Percentage      
(%) 
Male 69 (63%) 
Female 40 (37%) 
TOTAL 109 (100%) 
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The ratio of male and female patients followed a similar trend when observed separately for 
various age groups with the male patients outnumbering the females. The highest incidence of 
bacterial meningitis was present in infants less than one year of age which accounts to about 29 
cases out of 109 (26.6%). This was followed by small children less than 4 years of age which 
constituted 25 cases (23%). Another peak was observed in the age group 25 to 39 years of age 
which made up 16.5% of the cases. 
 
 
Figure 5: Cases of bacterial meningitis in Gondar University Hospital 
during 2007-2011 
AGE GROUP 
GENDER 
TOTAL MALE FEMALE 
 Infants               
(0-12 months) 
No. of cases (N) 17 12 29 
%  (58.6%) (41.4%) (26.6%) 
1-->4 years No. of cases (N) 15 10 25 
%  (60.0%) (40.0%) (22.9%) 
5-->9 years No. of cases (N) 9 3 12 
%  (75.0%) (25.0%) (11%) 
10-->14 years No. of cases (N) 9 2 11 
%  (81.8%) (18.2%) (10%) 
15-->24 years No. of cases (N) 4 2 6 
%  (66.7%) (33.3%) (5.5%) 
25-->39 years No. of cases (N) 9 9 18 
%  (50.0%) (50.0%) (16.5%) 
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40-->59 years No. of cases (N) 6 0 6 
%  (100.0%) (0.0%) (5.5%) 
60+ years No. of cases (N) 0 2 2 
%  (0.0%) (100.0%) (1.8%) 
Total No. of cases (N) 69 40 109 
%  (63.3%) (36.7%) (100%) 
 
4.1.2. Seasonal effect on the incidence of bacterial meningitis: 
In Gondar University Hospital among the 128 cases of bacterial meningitis, the highest incidence 
occurred during the summer months of May and June which had 21 and 28 cases, together 
forming more than 35% of the cases. The months immediately preceding the summer months 
also had higher number of cases with March and April together making up 21% of the total 
cases. The latter half of the year after the summer months had comparatively few cases with only 
23% of the cases occurring during the 5 months period from August to December.    
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4.1.3. Organisms of bacterial meningitis: 
The organisms causing bacterial meningitis was identified in 128 cases in Gondar University 
Hospital during 2007 to 2011. Bacterial cultures were performed on 99 cases out of these 128 
patients and 62 patients were confirmed on the basis of Gram staining results. Both culture 
results as well as Gram staining results were carried out to diagnosis 33 cases. 
 
  
44 
 
Table 6: Laboratory confirmation of cases of bacterial 
meningitis in Gondar University Hospital during 2007-2011 
Cases confirmed by both by culture and Gram 
staining 
33 
Cases confirmed by only by culture 66 
Cases confirmed only by Gram staining 29 
TOTAL 128 
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The culture results from Gondar University Hospital showed the highest incidence of S. 
pneumoniae among the common agents of bacterial meningitis. S. pneumoniae was isolated 
from the CSF cultures of 35 patients (35.3%). N. meningitidis was isolated from 27 cases 
(27.3%) and H. influenzae from 9 cases (9.1%). A variation in the incidence of these agents of 
bacterial meningitis was observed in various age groups. Most marked variation was observed 
with H. influenzae and some less common organisms of bacterial meningitis such as E. coli, 
which were more common in infants. All the 9 identified cases of H. influenzae were present in 
children less than 14 years of age, 5 of them in infants. The incidence of S. pneumoniae 
remained almost constant between the various age groups. Both S. pneumoniae and N. 
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meningitidis showed comparatively less variations in the various age groups. However, they 
were most commonly observed in the young children between 1-4 years of age where N. 
meningitis and S. pneumoniae were isolated from CSF of 9 and 8 patients, respectively. 
Variation in the incidence of the various agents of bacterial meningitis according to the various 
age groups is depicted in figure 7. The median ages for the various culture confirmed cases are 
presented in table 7. 
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Table 7: Median age for the culture positive cases at Gondar University   
Hospital during 2007 -2011 
Organism Median Age  No. of cases (n) 
(Range) 
N. meningitidis 5 years n = 27 
(Range = 0 month – 40 years) 
S. pneumoniae 7 years n =35 
(Range= 0 month – 48 years) 
H. influenzae 1 month n =9 
(Range= 0 month – 14 years) 
Other organisms 3.5 years n =28 
(Range = 0 month – 57 years) 
 
Less common organisms were also isolated from the CSF samples of 28 patients of bacterial 
meningitis at Gondar University Hospital. Out of these 28 cases E. coli was the most common 
organism and was isolated from the cultures of 8 patients. The next common organisms were S. 
aureus and Salmonella sp. that were isolated from 4 and 3 cultures, respectively. The various 
uncommon agents of bacterial meningitis that were isolated from cultures of patients of 
bacterial meningitis at Gondar University Hospital are presented table 8.  
 
Table 8: Uncommon causes of bacterial 
meningitis in patients of Gondar University 
Hospital during 2009-2011 
Organism Number of 
cases (N) 
E. coli 8 
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S. aureus 4 
Salmonella sp. 3 
Acinetobacter 2 
S. pyogenes 1 
Other Streptococci 2 
Pseudomonas 1 
Providencia sp 1 
Morganella morganii 1 
K. pneumonia 1 
Enterobacter 1 
Cryptococcus neoformans 1 
Not identified 2 
TOTAL 28 
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Positive Gram staining results were used to assist the clinical diagnosis in 62 cases at the Gondar 
University Hospital. About half of these Gram staining results (33 cases) were also supported by 
positive bacterial cultures. Gram staining results from the CSF specimens of patients at Gondar 
University Hospital along with the bacterial morphological features are presented in table 9. The 
most commonly observed results were Gram positive cocci that were observed in 28 cases 
(45.2%). Gram negative diplococci were the second most common observed morphology and 
were seen in 20 cases (32.3%). Gram negative rods were seen only in 14 cases which makes 
22.6% of the total cases.  
 
Table 9: Gram Staining Result from CSF samples of 
patients in Gondar University Hospital during 2007-2011 
Gram staining result Number of 
cases (N) 
Percent   
(%) 
Gram positive cocci 28 45.2 
Gram negative diplococci 20 32.3 
Gram negative rods 14 22.6 
Total 62 100.0 
 
4.1.4. Seasonal variations among the various agents of bacterial meningitis: 
The bacterial culture results from Gondar University Hospital were used to interpret the effect of 
seasonal variations on the prevalence of the organisms causing bacterial meningitis. The whole 
calendar year was broken down into 4 quarters to assess the effect of change in weather 
conditions on the common agents of bacterial meningitis. The most marked seasonal variation 
was observed for N. meningitidis which had a high incidence in the 2
nd
 quarter (April to June). 
During the dry season (April to June) 18 cases were confirmed by culture results as compared to 
very few cases in other quarters. When the cases were split according to the time of presentation 
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the highest incidence was observed in the month of June where culture from 8 CSF specimens 
revealed N. meningitidis. The incidence of N. meningitidis dropped drastically during the winter 
months from October to December. The seasonal variation on the incidence of bacterial 
meningitis is shown in the figure 8. 
  
 
 
Apart from N. meningitidis, all the other organisms of bacterial meningitis showed little variation 
during the four quarters of the year. The incidence of S. pneumoniae varied between the highest 
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of 14 cases in the 2
nd
 quarter to lowest of 5 cases in the 3
rd
 quarter. H. influenza and other less 
common organisms did not show considerable variation in the different seasons of the year. 
Figure 9 presents the incidence of the various agents of bacterial meningitis during the 4 quarters 
of the year as observed in the culture positive results from Gondar University Hospital during the 
5 years study period. 
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4.2. Awassa Referral Hospital: 
The clinical record files from the hospital’s in-patient and emergency wards and the laboratory 
records identified 143 cases of bacterial meningitis at Awassa Referral Hospital from September 
2009 to the end of December 2011. These 143 cases include the laboratory diagnosed cases as 
well as the cases that were clinically confirmed based on the signs and symptoms. The data 
collected from the clinical record files of these patients were used to study the demographical 
trends of bacterial meningitis as well as the clinical features and the outcome of treatment.   
4.2.1. Age wise and sex wise distribution of bacterial meningitis: 
Out of 143 cases, 94 were males and 49 were females making a male to female ratio of 1.9:1. 
The trend was uniform in all age groups with more case occurring among males. The highest 
number of cases were in the young adults between the age 15 to 24 years. In this age group 38 
cases (27%) of bacterial meningitis were observed. This was followed by adults between the age 
of 25-39 years which constitutes 29 cases (20%). Only 32 cases (22%) were children less than 4 
years of age, half of which were infants less than one year of age. The median age recorded was 
20 years (Age range = 0 months – 65 years).   
 
 
Table 10: Age-wise and sex-wise distribution of cases at Awassa 
Referral  Hospital during September 2009 – December 2011 
 
AGE GROUP 
GENDER  
TOTAL MALE FEMALE 
Infant  
(0-12 months) 
No. of cases (N) 
Percentage (%)  
12 
(75.0%) 
4 
(25.0%) 
16 
(11.2%) 
1-->4 years No. of cases (N) 
Percentage (%) 
8 
(50.0%) 
8 
(50.0%) 
16 
(11.2%) 
5-->9 years No. of cases (N) 
Percentage (%) 
9 
(75.0%) 
3 
(25.0%) 
12 
(8.4%) 
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10-->14 years No. of cases (N) 
Percentage (%)  
8 
(61.5%) 
5 
(38.5%) 
13 
(9.1%) 
15-->24 years No. of cases (N) 
Percentage (%)  
27 
(71.1%) 
11 
(28.9%) 
38 
(26.6%) 
25-->39 years No. of cases (N) 
Percentage (%) 
16 
(55.2%) 
13 
(44.8%) 
29 
(20.3%) 
40-->59 years No. of cases (N) 
Percentage (%) 
9 
(64.3%) 
5 
(35.7%) 
14 
(9.8%) 
60+ years No. of cases (N) 
Percentage (%) 
5 
(100.0%) 
0 
(0.0%) 
5 
(3.5%) 
Total No. of cases (N) 
Percentage (%) 
94 
(65.7%) 
49 
(34.3%) 
143 
(100%) 
 
 
 
4.2.2. Effect of seasonal variation of the incidence of bacterial meningitis: 
In order to assess the effect of seasonal variation on the incidence of bacterial meningitis in 
Awassa, two years data from January 2010 to December 2011 were studied (represented in 
figure 10). A fairly uniform pattern was observed throughout the year: the incidence remained 
constant during this time. However, the highest number of cases were recorded in April (15 
cases) with almost 12% of the cases. This was followed by November which has 13 cases (11%).  
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4.2.3. Clinical feature of bacterial meningitis:  
Patients with bacterial meningitis presenting at Awassa Referral Hospital during the two and a 
half year study period were studied to find out the incidence of various common signs and 
symptoms of bacterial meningitis. The relative frequency of each of the common signs and 
symptoms were recorded for 135 cases. The most common symptom was fever. High grade fever 
(>38
o
C) was recorded in 120 cases (88.9%). The second most common sign was neck stiffness 
which was present in 101 cases (74.8%). Headache and nausea or vomiting were present in 94 
and 80 cases, respectively. Altered mental state such as un-consciousness, behavior change or 
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inability to speak was observed in more than half of the patients. Almost 36% of the cases were 
reported to have had one or more incidence of seizures before presenting to the hospital. 
Respiratory symptoms such as cough, wheezing or effort breathing were present in less than a 
quarter of the patients.  
 
Table 11: Clinical symptoms at presentation in patients of bacterial 
meningitis at Awassa Referral Hospital during Sep 2009 to Dec 2011 
Sign and symptoms Frequency Percentage (%) 
Fever >38
0
C 120/135 88.9 
Neck stiffness 101/135 74.8 
Headache 94/135 69.6 
Nausea and Vomiting 80/135 59.3 
Altered mental state 70/135 51.9 
Seizures 48/135 35.6 
Respiratory symptoms 33/135 24.4 
Shock 6/135 4.4 
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4.2.4. Outcome of bacterial meningitis: 
The clinical files of 143 cases of bacterial meningitis at Awassa Referral Hospital were studied 
to find out the outcome of the treatment. Final treatment outcomes were recorded in 119 cases. 
The most common outcome of the treatment was complete recovery which was observed in 80 
(56.6%) out of 119 cases. Death was the second most common outcome with 28 cases recorded 
as fatal cases. Neurological or other sequelae were present in 11 cases at the time of discharge 
from the hospital.  
Outcome could not be recorded in the remaining 24 cases. Out of these 24 cases, 6 cases with 
severe life threatening illness were referred to Addis Ababa for further investigation and 
management. Treatment outcome could not be recorded in 7 cases which intentionally withdrew 
from the treatment and were discharged against the advice of the attending physician. In an 
additional 11 cases the medical records from the clinical files were insufficient to reveal the final 
outcome of the treatment.    
  
57 
 
 
 
 
4.2.5. Adverse outcomes of bacterial meningitis: Death 
During the study period 28 deaths were recorded due to bacterial meningitis, thus giving a case 
fatality rate (CFR) of 23.5%. These fatal cases were then further analyzed by breakup into the 
various age groups. Most of the fatal cases were in infants or young adults. When age specific 
CFRs were studied, infants had the highest CFR of 41.6%. A CFR of 33.3% was recorded in 
older patients above 60 years of age. This was followed by the children between the age groups 
of 4 to 9 years and 10 to 14 years. A higher CFR of 30% was observed in these age groups. A 
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gender-wise breakdown of the fatal cases showed that more deaths were recorded in males then 
females. Results show that 19 out of 94 male patients died due to bacterial meningitis during the 
two and a half year study period at Awassa Referral Hospital as compared to 9 deaths in a total 
of 49 females that presented during the same period. This gives a male to female CFR of 1.1:1.  
 
Table 12: Fatal cases of bacterial meningitis at Awassa Referral Hospital during 
September 2009 - December 2011 
 
AGE GROUP 
CASES WITH 
KNOWN 
OUTCOMES 
(N) 
DEATHS IN 
EACH AGE 
GROUP 
(D) 
CASE FATALITY 
RATE (CFR) 
 
NO. OF DEATHS  X 100   
NO. OF CASES 
Infant (0-12 months) 12 5 41.6% 
1-->4 years 12 1 8.1% 
5-->9 years 10 3 30.0% 
10-->14 years 10 3 30.0% 
15-->24 years 35 8 22.8% 
25-->39 years 25 5 20.0% 
40-->59 years 12 2 16.6% 
60+ years 3 1 33.3% 
Total 119 28 23.5% 
 
4.2.6. Adverse outcomes of bacterial meningitis: Sequelae 
Complications of bacterial meningitis were recorded at the time of hospital discharge in 11 cases 
(7.7%). The most common sequelae were neurological complications such as paralysis or 
weakness of the limbs (4 cases); facial palsy (4 cases), muscle wasting (2 cases), deafness or 
hearing impairment (2 cases) and acute psychosis (2 cases).  
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Chapter five: DISCUSSION AND RECOMMENDATIONS: 
 
5.1.  Discussion: 
The aim of the study was to explore the various demographical, epidemiological and clinical 
aspects of the bacterial meningitis in Ethiopia. The results are based on 128 cases from a 5-year 
period (2007 to 2011) from Gondar University Hospital. These 128 cases include only those 
cases that had been confirmed by laboratory identification of the causative organism. The data on 
clinical signs and symptoms and the treatment outcomes represent a two and a half year 
(September 2009 to December 2011) data of the 143 patients at Awassa Referral Hospital.  
The data on 128 laboratory confirmed cases of bacterial meningitis from Gondar University 
Hospital showed marked male predominance (male to female ratio of 1.7:1). The data from 
Awassa reveal an even higher incidence in males (male to female ratio of 1.9:1). Throughout the 
various age groups the trend of male predominance tends to persist. Various large scale studies 
conducted worldwide show a higher incidence in males. A study on the characteristics of 
bacterial meningitis was conducted in four major tertiary care hospitals in Bangladesh during 
2003 and 2004 
(124)
. The study showed that out of 1841 cases, 1307 were males, giving a male to 
female ratio of 2.5:1. Similarly, studies from Ethiopia have also shown a higher incidence in 
males. A 5-year retrospective study conducted in Gondar University Hospital during 1998 to 
2003 identified 151 children with bacterial meningitis 
(65)
. This study also reported a higher 
incidence in males with a male to female ratio of 2:1. During the meningococcal epidemic in 
Gondar in 2001-2002, a total of 1619 probable cases of meningococcal meningitis were reported. 
Out of these 1619 cases, 960 were males (male to female ratio of 1.5:1)
 (125)
. The comparison 
between this Gondar study and our study shows a much higher number of patients of bacterial 
meningitis in the former study. The reason for this higher number of cases is due to the inclusion 
of probable cases which were not laboratory confirmed. The current study focuses on the 
etiology and has only included the laboratory confirmed cases from Gondar which were 
confirmed either by CSF culture or Gram staining. This explains the difference in the number of 
cases in these two studies from Gondar.  
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What has caused this high male to female ratio at both of the study sites may be linked to various 
factors. As seen in the literature and from results of the studies mentioned above, the organisms 
of bacterial meningitis show susceptibility patterns indicating a higher affinity for males. This 
fact may be exaggerated in the settings where males have more access to the health care 
facilities, as is presumed to be the cases in this study. The social and cultural factors favor easier 
access for males to the healthcare facilities as compared to the females which are more 
dependent on the males for travelling to far-located health care centers. Other barriers that may 
have affected the female access to the hospitals include fewer financial resources and the 
additional responsibilities in the family such as caring for children. The data show a greater 
difference in the number of patients of both genders in the infants and small children. At Awassa 
75% of the infants were males. This may also highlight the bias or the preference that may be 
given by the family to the male children over the female children.  
Bacterial meningitis is generally a disease of childhood. In this study the most commonly 
affected age group was found to be the infants and small children less than 4 years of age. Data 
from Gondar University Hospital show that almost half of the cases (49.5%) were either infants 
or children less than 4 years of age. Results from Awassa Referral Hospital show the highest 
incidence in young adults 15-24 years of age which make 27% of the total cases. Children less 
than 4 years of age, including the infants, make 22% of the cases. Within the various age groups, 
a higher incidence in infants has frequently been reported in literature. A 10-year study 
conducted in United States in California during 1998 to 2007 showed the highest incidence of 
bacterial meningitis in infants less than 2 months of age 
(126)
. For the year 2006-2007 the 
incidence was 80.7 cases per 100,000 population. Children greater than 2 months and less than 2 
years of age showed the second higher incidence (6.9 cases per 100,000 population) during the 
same year. A large scale retrospective study in Niger showed that in the year 1995-96 
(127)
 the 
incidence of bacterial meningitis was highest in infants less than one year of age (638 cases per 
100,000 population), this was followed by children between 1-4 years of age (490 cases per 
100,000 population). Older children between 10-14 years and young adults also showed a higher 
incidence (each having 476 cases per 100,000 population). In contrast to these studies, a study in 
North Gondar during 2001-2002 showed the highest incidence in young adults between 15-30 
years of age (52% of cases) 
(125)
. Generally, these results point out at 2 peaks of age that have 
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high susceptibility for bacterial meningitis i.e. small children and young adults. This also 
parallels with the findings in this current study.  
Certain agents of bacterial meningitis are known to have higher affinity for some age groups, 
particularly H. influenzae, which commonly effects infants. The results of this study from 
Gondar show a similar trend in which H. influenzae was more prevalent in the infancy and 
younger children (all 9 culture confirmed cases were less than 14 years). Little variation in the 
various age groups was observed for N. meningitidis and S. pneumoniae, both of which showed 
only a slightly higher incidence in small children between 1-4 years of age. This trend in the 
different age groups for these common organisms has frequently been reported in literature. A 
study was conducted in Lazio, Italy during the period 2001–2005 to study these variations in age 
groups. A slight variation in various age groups was reported for N. meningitidis and S. 
pneumoniae. S. pneumoniae had a higher incidence at both extremities of age whereas N. 
meningitidis was more prevalent in smaller children less than 4 years. Marked variation was only 
observed for H. influenzae which had a considerably higher incidence in smaller children less 
than 4 years (25 out of 46 cases) 
(128)
. Similar results were observed in a study on the laboratory 
based surveillance of bacterial meningitis in Sudan during the year 2004-2005. The study 
showed that out of a total of 24 culture or PCR confirmed cases of H. influenzae, 21 (87.5%) had 
occurred in children less than 5 years of age 
(11)
.           
Seasonal variations are typical of meningococcal meningitis but may occur to a lesser extent with 
other agents of bacterial meningitis 
(100)
. The dry season starting from December and reaching up 
till June has invariably been implicated in meningococcal epidemics. When the data from the 
study sites were analyzed the highest incidence for meningitis cases was observed in the summer 
months. At Gondar University Hospital 35% of the meningococcal meningitis cases presented in 
the months of May and June and tapered markedly as the winter season approached. The cases 
peaked in second quarter of the year (April to June), followed by a steep decline in the incidence. 
This coincides with our knowledge of the seasonal variation in the incidence of meningococcal 
meningitis in the countries of meningitis belt. However, such sharp decline in the cases of 
bacterial meningitis was not so apparent in Awassa. This may partly be due to the fact that the 
data from Awassa represents bacterial meningitis as a whole and the cases of meningococcal 
disease could not be studied separately due to the very few cultures performed. As all the agents 
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of bacterial meningitis do not exhibit seasonal variations to similar extent, therefore, when all the 
agents of bacterial meningitis were studied collectively, the masking of the seasonal effect on the 
incidence of meningococcal disease can be an important factor.          
The agents causing bacterial meningitis may vary considerably depending upon the geographical 
and climatic conditions, socio-economic status and importantly the immunization schemes in the 
host community 
(16)
. Culture results from Gondar University hospital reveal the prevalence of 
various organisms that cause bacterial meningitis. Almost 35% of the cultures were identified as 
S. pneumoniae, followed by N. meningitidis and H. influenzae which are isolated from 28% and 
9% of the cases, respectively. The predominance of these three agents of bacterial meningitis has 
widely been reported in literature. A large scale WHO study conducted in various countries of 
meningitis belt including Ethiopia has documented similar patterns with S. pneumoniae being the 
most common organism. It was identified in 26% of the cases. S. pyogenes (20%) and E. coli 
(18%) were the other common organisms 
(121)
. A laboratory based study on the surveillance of 
bacterial meningitis in Egypt during 1998-2004 depicted a high S. pneumoniae prevalence (42%) 
followed by Hib (20%) and N. meningitidis (16%) 
(129)
. The etiology of bacterial meningitis may 
vary with the age of the study group and other characteristics of the population. A 5-year study 
on children up to the age of 14 years in Gondar during 1998-2003 reported N. meningitidis as the 
leading cause of bacterial meningitis (27.8% of the cases). S. pneumoniae and H. influenzae were 
present in 7.1% and 5.6% of the cases 
(65)
.  
The results from these studies show varying etiological trends subjected to multiple factors, 
therefore, an estimate of the prevalence of these causative organisms can often be very complex. 
A study was conducted by Norwegian Institute of Public Health in North Gondar and SNNPR 
Ethiopia in 2002 and 2003 
(78)
. A total of 95 cases were included with the aim of characterization 
of N. meningitidis from these isolates. Out of 95 cases 71 cases were identified as N. 
meningitidis. The remaining 24 cases were identified in February-March 2012 by Real-Time 
PCR as a part of this thesis. (Please refer to appendix II to find a detailed account on the RT-PCR 
results from those samples). 
It is evident from the literature on bacterial meningitis in the meningitis belt countries that in the 
lack of availability of laboratory facilities the clinical signs and symptoms play a significant role 
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in the diagnosis of bacterial meningitis. The classic triad of symptoms i.e. fever, headache and 
neck stiffness are characteristic of bacterial meningitis 
(61)
.  These were the most common signs 
and symptoms that were recorded in the clinical record files of the patients in Awassa Referral 
Hospital. Fever was present in 90% of the cases and 75% of the patients had neck stiffness. 
Headache was the presenting complaint in almost 70% of the cases. Petechial rash which is a 
characteristic of meningococcal sepsis occurred only in a single patient. A very similar study 
conducted on a 5-year retrospective clinical data in East England during 2005-2010 
(130)
 showed 
the highest prevalence of fever and headache (82% each), followed by altered mental state 
(59%), vomiting (51%), neck or back rigidity (33%). The results follow almost a similar trend as 
observed in the current study. However, in the East England study, 10 out of 39 cases (26%) had 
purpuric rash, in contrast to only one documented cases of petechial rash in the current study.    
The darker skin color may offer some hindrance in spotting petechial rash and this may be a 
contributing factor to the lower incidence of the rash at our study sites. As it has already been 
mentioned in the literature, that the most common serogroup of N. meningitidis in Ethiopia is 
serogroup A; 
(29)(30)
 a serogroup which is not usually associated with petechial rash. As the rash 
is a manifestation of severe meningococcal sepsis and a tertiary care hospital may often be 
located very far so some of these serious patients may even expire before reaching the hospital. 
All these reason may explain the reduced incidence of petechial rash observed in this study.     
Data on the clinical outcomes of treatment from Awassa Referral Hospital show a fatality rate 
(CFR) of 23.5%. When compared with different studies conducted around the world the CFR 
may be highly variable. In the developed world the CFR may be considerably lower than the 
CFR observed in this study. In a study conducted in the United States during 2003-2007, a CFR 
of 6.9 was observed in pediatric patients whereas a CFR of 16.4 was recorded in adult patients 
(126)
.  But earlier studies from Ethiopia have reported a fatality rate of 22-28% 
(114)
. But even the 
CFR reported in various studies in Ethiopia varies. In a study on 151 cases of bacterial 
meningitis in Gondar, 20 patients died, thus giving a CFR of 13.2% 
(65)
. The exact estimation of 
the fatality rates due to bacterial meningitis may be somewhat difficult as not all the cases 
present in the hospitals. These rates represent data from a tertiary care hospital with relatively 
better facilities. In isolated smaller healthcare units with minimal facilities the fatality rates may 
actually be much higher.  
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As in the case of CFR, the rate of sequelae may also be much lower in tertiary care hospitals. 
This may be the reason for a considerably lower rate of sequelae (9.2%) that was observed in this 
study as compared to the estimated rates that have been mentioned in the literature (up to 50%)
 
(69)
. The most commonly observed sequelae in the current study were neurological complications 
such as paralysis or weakness of the limbs (4 cases); facial palsy (4 cases), muscle wasting (2 
cases), hearing impairment (2 cases) and acute psychosis (2 cases). The same sequelae, but to a 
varying degree, have been reported in various studies. A systematic review of 37 studies from 21 
African countries has documented sequelae rate as high as 37% 
(66)
. The rate was higher with Hib 
and S. pneumoniae (44% and 38%, respectively). Therefore, the chances of sequelae may be 
highly variable depending upon the treatment facilities, age of the patient (more common in 
children) and also the organism causing infection as mentioned earlier. Early detection and 
timely treatment is therefore essential for the prevention of these long-lasting sequelae.   
 
5.2. Limitations of the study: 
Throughout the study, the emphasis has particularly been on the efforts to ensure the quality, 
validity and generalization of the data. Nevertheless, the study is not without its own limitations. 
Some main limitations that were encountered during the conduct of this study are listed.  
1. Due to the lack of availability of laboratory facilities, not all the cases were confirmed by 
laboratory evidence of the bacterial organism. In such instances the diagnosis was based 
solely on the clinical diagnosis which may be less accurate then the laboratory assisted 
diagnosis. 
 
2. The study period was highly dependent on the availability of the clinical and laboratory 
records. The limited data on the laboratory results along with relatively few CSF cultures 
and Gram staining confirmed cases were encountered as the major limiting factors, 
particularly in Awassa. As the laboratory facilities are still developing, therefore, the very 
recent records had relatively more laboratory confirmed cases as compared to earlier 
records. Therefore, in order to utilize the data effectively the study period had to be 
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tailored for each study site. This may have an effect on the uniformity of the study 
design.   
 
3. Both the study sites that were selected were tertiary care hospitals in larger cities with 
relatively better healthcare facilities than many other parts of the country. The situation in 
the periphery of these cities and more so in the remotely located villages may be entirely 
different. This fact may interfere to some extent with the generalization of the results.  
 
4. Another limitation may be the retrospective nature of the study itself. This implies relying 
on the quality and quantity of information that had already been recorded in the hospital 
and laboratory records. Some information loss may have occur at multiple steps starting 
from the data recorded by attending physician, laboratory staff and finally while 
recording the data onto the case record forms.  
 
5. The actual data was not computerized and was rather handwritten manuscripts of clinical 
and laboratory data entered by various physicians and laboratory staff. Reading and 
interpreting the original data was often difficult. However, to minimize this limitation 
help was always sought from a person working in the same settings and who was familiar 
with the data. 
 
6. The laboratory records were distributed in various logbooks belonging to different 
departments of the laboratory. Often the data were recorded randomly and haphazardly in 
these log books without a proper uniform pattern. This may increase the chances of 
missing some data or on the contrary the duplication of the data. The hospital registration 
numbers and admission dates were used to prevent any possible duplication.  
 
7. The data were entered in predefined data collection forms (attached as appendix I). This 
may result in loss of some important information that was not accounted for on the data 
collection forms. 
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8. As the study was retrospective and follow up was not a problem, but still some of the 
cases were either referred or were discharged against medical advice. In such patients the 
final outcome of the treatment could not be recorded.        
 
5.3.  Future recommendations: 
The research on bacterial meningitis in the meningitis belt countries has evolved persistently in 
the past years. The new knowledge thus obtained has reshaped our struggle against meningitis 
and undermines the current and future preventive strategies. This study has been conducted with 
an aim to pave way for future studies in similar settings. Following are the recommendation from 
this study: 
1. Similar studies in settings with better laboratory facilities may yield more information on 
the recent incidence of the causative organisms or the current serotypes. Combining the 
laboratory results with the clinical outcome will help in better understanding of bacterial 
meningitis. 
 
2. Studies focusing on other hospitals of Ethiopia may provide results specific to other parts 
of Ethiopia. This will be beneficial not only to the respective hospital but also the 
Ethiopian population as a whole. 
 
3. Many patients of bacterial meningitis may not present at tertiary care hospitals due to vast 
distances from hospitals and lack of transport facilities. Any study that has its focus laid 
primarily on the primary healthcare centers in the peripheries will provide valuable 
information on a large portion of cases that are easily missed when studies are conducted 
only in the tertiary care hospitals. 
 
4. During the course of study many patients with co-existent infectious diseases were found. 
The association of bacterial meningitis with other infectious diseases such as Human 
Immunodeficiency Virus (HIV) infection or in immunocompromised patients may need 
further exploration.   
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5. Standardization of the data entry procedures for hospitals’ clinical and laboratory records 
at the study sites along with a more unified collection and storage of records will certainly 
prove beneficial for the follow up patients, the hospital staff and even the future 
researchers working on disease prevention in these settings.      
 
6. Finally, the laboratory techniques to identify the causative organism form the basis of 
treatment of bacterial meningitis. Laboratory surveillance is essential for the control of 
meningitis due to continuously changing epidemiology of the disease in the meningitis 
belt countries. Limitation of resources and lack of properly trained staff form the main 
reason for the underutilization of these laboratory techniques. A steady and step wise 
increase in the utilization of these techniques will not only provide prompt and accurate 
diagnosis for the patients but will also serve as a more reliable indicator of bacterial 
meningitis trends in the host population.   
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Appendix I: Retrospective data collection form: 
Study title: “Surveillance of bacterial meningitis in Ethiopia and examining factors affecting meningococcal disease 
severity.” 
RETROSPECTIVE DATA COLLECTION FORM  
 
PATIENT DATA 
 
HOSPITAL NAME: 
 
AGE:    
 
SEX: 
PATIENT ID: 
 
DATE OF ADMISSION: 
 
CITY/REGION: 
 
CLINICAL SYMPTOMS AT THE TIME OF ADMISSION 
FEVER (TEMP > 38
0
C)  ALTERED MENTAL STATE 
 
 
HEADACHE  SEIZURES 
 
 
NAUSEA/VOMITING  SHOCK 
 
 
STIFF NECK/BACK STIFFNESS  PETECHIAL RASH 
 
 
 
CLINICAL DIAGNOSIS: 
 
TREATMENT OUTCOME 
 
COMPLETE RECOVERY:   
 
PARTIAL RECOVERY WITH SEQUELAE:    
(SPECIFY SEQUELAE)  
FATAL CASE DATE:   
 
LABORATORY FINDINGS 
TEST DONE RESULT 
 
CSF GRAM STAINING: 
 
 
 
POSITIVE     
NEGATIVE   
 
MORPHOLOGY: 
 
CSF CULTURE: 
 
 
 
N. meningitidis                  H. influenzae     
S. pneumoniae                            Others      
 
CSF CELL COUNT 
PROTEINS AND 
GLUCOSE LEVEL 
 
 
 
 
CSF  CELL COUNT: ____________ /mm
3
 
PROTEINS CONC:   ____________ g/liter 
GLUCOSE CONC:    ____________ g/liter 
OTHER LABORATORY FINDINGS: 
 
DATA COLLECTED BY:                                             CROSS CHECKED BY 
  
ii 
 
Appendix II: Characterization of etiological agent from Ethiopian CSF 
samples from 2002-2003 by RT-PCR: 
Real time PCR is a modification to the ordinary PCR that allows continuous observation of the 
increase in the amount of DNA during its amplification. After its introduction in late 1990’s, RT-
PCR has revolutionized the field of clinical microbiology. Mentioned hereunder are the results 
from Real-Time PCR that was applied to the Ethiopian samples from 2002 – 2003. The analysis 
was conducted with the help of the laboratory staff at Norwegian Institute of Public Health 
(NIPH). This work is seen as an important achievement not only in terms of the characterization 
or defining of etiology of bacterial meningitis in Ethiopia but more importantly, as an 
acquaintance with the modern laboratory techniques. The training received and the successful 
implementation of this training onto the samples is regarded as a significant byproduct of the 
project and an important additional learning of the laboratory techniques that form an important 
component of the modern day diagnostic procedures for the diagnosis of bacterial meningitis. 
The project co-ordinators from NIPH including Gunnstein Norheim and the principal 
investigator for the current project Prof. Dominique A. Caugant had conducted a study in 2002 
and 2003 in North Gondar and Southern Nations, Nationalities and Peoples’ Region (SNNPR) of 
Ethiopia 
(78)
.  A total of 95 cases were included between April 2002 and December 2003 with the 
aim of characterization of N. meningitidis from these isolates. Bacterial cultures on the CSF and 
PCR were used to identify N. meningitis and to further study the serotypes. Out of 95 samples 71 
were confirmed as N. meningitidis. The remaining 24 samples were undetermined except one 
sample that was identified as H. influenzae type b on the basis of culture results. The etiology of 
the remaining 23 samples remained undetermined. 
The remaining 23 samples from 2002 and 2003 were analyzed in February-March 2012 by Real-
Time PCR as part of this Master’s degree. Originally, these 23 samples had tested negative for N. 
meningitidis when run on standard PCR in 2003 and were not tested by PCR for the presence of 
other etiological agents. To find the presence of other possible etiological agents, these samples 
were now purified using QIAGEN kits and were then run on the 7500 Fast System. Multiple runs 
were conducted initially using singleplex and later on by multiplex PCR. The genes amplified 
  
iii 
 
were ctrA for N. meningitidis, lytA for S. pneumoniae and bexA and omp for H. influenzae. The 
real-time results were analyzed using the 7500 Fast System SDS Software. Positive and negative 
controls were used along with an internal positive control in each run of PCR. Out of 23 samples 
analyzed, the etiological agent was identified for 8 samples. Out of these 8 cases, S. pneumoniae 
was confirmed in 5 samples and H. influenzae in the remaining 3 samples. These results when 
combined with the original results from the study in 2002 and 2003 give 71 cases of N. 
meningitidis followed by 5 cases of S. pneumoniae and 4 cases of H. influenzae. The remaining 
15 cases tested negative for these organisms.  
Although the results provide information on the etiology of bacterial meningitis, the main aim 
was to familiarize with the steps involved in real-time PCR. The opportunity to work with the 
highly trained staff and the practical utilization of the theoretical knowledge may prove helpful 
in conducting research in future.    
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Realtime PCR results showing DNA amplification in Ethiopian samples along with positive controls. 
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Real time PCR results showing higher amplification for omp gene in one of the Ethiopian samples in 
comparison to a positive H. influenzae control. 
 
